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ABSTRACT 
Nowadays, cancer is a major, worldwide problem, affecting both developed and 
developing countries. Despite the incredible amount of research spanning this field, the 
statistics on cancer are not optimistic. Leukemia is a type of cancer with a worldwide incidence 
of 2.5% and a mortality rate of 3.4% (out of all cancers). Chronic myeloid leukemia (CML) 
represents 15 - 20% of all new cases of leukemia and is characterized by an uncontrolled 
proliferation of myeloid cells. Currently, the first-line of treatment involves tyrosine kinase 
inhibitors (TKI), which act in a specific way to inhibit the activity of BCR-ABL. However, 
resistance, mainly due to mutations, can occur. When the disease reaches a more advanced 
stage – the blast crisis – more aggressive chemotherapeutics are applied, such as 
anthracyclines. Doxorubicin is an example that is used in several types of cancers, including 
leukemia, yet the action of this drug can also cause resistance and other important issues such 
as non-targeted cytotoxicity. In the attempt to find more effective and less toxic therapies, two 
in vitro approaches were explored in this work: (i) the study of the anticancer activity of natural 
compounds; and (ii) the (less explored) improvement of current therapy combined with natural 
compounds. 
Marine organisms are a rich source of bioactive compounds with diverse biological 
activities. Several compounds isolated from seaweed, namely carotenoids and phlorotannins 
present anticancer activity against numerous cancer cell lines. In the current work, the in vitro 
anticancer activity of fucoxanthin and phloroglucinol alone and co-incubated with anticancer 
drugs (imatinib and doxorubicin) was assessed on two human cancer cell lines (K562 and TK6) 
derived from blast crisis of CML. For this (i) cytotoxicity at short time; (ii) proliferation capability; 
(iii) induction of DNA damage; and (iv) induction of cell death by apoptosis, were evaluated. 
Our results showed that doxorubicin was more cytotoxic than imatinib in both cell lines. Both 
anticancer drugs decreased cell proliferation in a dose-dependent manner in K562 cell line 
without induction of DNA damage or apoptosis. Proliferation inhibition of TK6 cell line induced 
by doxorubicin was accompanied by an increase of DNA damage and apoptosis. Furthermore, 
fucoxanthin decreased cell proliferation without effects on DNA damage or apoptosis in both 
cell lines. When co-incubated with the anticancer drugs the inhibition was not improved when 
compared with fucoxanthin alone for both cell lines. Phloroglucinol did not show cytotoxic effect 
at short time in both cell lines, however, in TK6 cells, phloroglucinol alone and co-incubated 
with imatinib inhibited cell proliferation, but without induction of DNA damage and apoptosis.  
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This work demonstrated that both the natural compounds exhibit antiproliferative effects 
against K562 (fucoxanthin) and TK6 (fucoxanthin and phloroglucinol) cell lines. When co-
incubated with the drugs (doxorubicin and imatinib) their efficacy was enhanced in certain 
conditions. The findings warrant more studies to understand the mechanisms of action involved 
in the antiproliferative effects of fucoxanthin and phloroglucinol in the cell lines tested. This 
knowledge could be interesting to explore the natural compounds as new adjuvant strategy for 
the treatment of cancer cells that share the same molecular characteristics that the cell lines 
evaluated in this work. 
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RESUMO 
Atualmente o cancro é um grande problema ao nível global, afetando tanto países em 
desenvolvimento bem como desenvolvidos. Apesar da incrível quantidade de pesquisa neste 
campo os dados estatísticos existentes são pouco otimistas. Em particular, a leucemia é um 
cancro com uma incidência de 2.5% e um índice de mortalidade de 3.4% em todo o mundo. 
Leucemia mielóide crónica representa entre 15 – 20% de todos os tipos de leucemia e é 
caracterizada pela proliferação descontrolada de células mieloides. Atualmente a primeira 
linha de tratamento para esta doença são os inibidores de tirosina quinase, estes atuam de 
uma forma bastante especifica inibindo a atividade do BCR-ABL, contudo pode ocorrer o 
aparecimento de resistências devido ao desenvolvimento de mutações. Quando a doença 
atinge um estado mais avançado – a fase ou crise blástica - quimioterapêuticos mais 
agressivos são aplicados, como é o exemplo dos antraciclinas. Doxorrubicina é uma 
antraciclina muito usada para tratar vários tipos de cancro, incluindo a leucemia, contudo a 
ação desta droga tem vindo a ser relacionada com o aparecimento de resistência e também a 
sua ação não específica torna-a tóxica para outras células (células normais). De maneira a 
tornar os tratamentos mais efetivos e menos tóxicos, duas abordagens in vitro foram 
exploradas neste trabalho: (i) o estudo da atividade anticancerígena dos compostos naturais; 
e (ii) o (menos estudado) melhoramento dos atuais tratamentos utilizados através da 
combinação com compostos naturais. 
Os organismos marinhos são uma fonte de compostos bioativos com diversas 
atividades biológicas. Alguns compostos isolados das algas, nomeadamente carotenóides e 
florotaninas, apresentam atividade anticancerígena contra diversas linhas celulares de cancro. 
No presente trabalho, a atividade anticancerígena in vitro da fucoxantina e floroglucinol 
sozinhos ou co-incubados com os fármacos anticancerígenos (imatinib e doxorrubicina) foi 
avaliada em duas linhas celulares cancerígenas (linha celular K562 e TK6) provenientes da 
fase blástica da leucemia crónica mielóide. Para isso, (i) a citotoxicidade de curta exposição; 
(ii) a capacidade de proliferação; (iii) a indução de danos no ADN; e (iv) a indução de morte 
celular por apoptose foram avaliados. Os nossos resultados mostraram que a doxorrubicina 
foi mais citotóxica do que o imatinib para as duas linhagens celulares. Ambos os fármacos, 
imatinib e doxorrubicina, diminuem a proliferação celular de uma forma dose-dependente nas 
K562 sem indução de danos no ADN e apoptose. A inibição da proliferação induzida pela 
doxorrubicina nas TK6 foi acompanhada por um aumento dos danos no ADN e da apoptose. 
Além disso, fucoxantina demonstrou uma redução da proliferação celular sem efeitos ao nível 
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dos danos no ADN ou na apoptose para ambas as linhas celulares. Quando co-incubada com 
os fármacos a inibição não aumenta quando comparado com o composto sozinho. 
Floroglucinol não mostrou citotoxicidade para curtos períodos de exposição em ambas as 
linhas celulares, contudo nas TK6 floroglucinol sozinho ou em co-incubação com imatinib inibiu 
a proliferação celular, mas sem induzir danos ao nível do ADN e apoptose. 
 Com este trabalho demonstramos que ambos os compostos naturais exibem um efeito 
antiproliferativo contra as K562 (fucoxantina) e TK6 (fucoxantina e floroglucinol). Quando co-
incubados com os fármacos (doxorrubicina e imatinib) a eficiência dos mesmos é melhorada 
em certas condições. Os achados justificam que se implementem mais estudos de modo a 
compreender quais os mecanismos de ação envolvidos nestes efeitos antiproliferativos da 
fucoxantina e do floroglucinol nas linhagens testadas. Poderá ser de interesse explorar este 
efeito de modo a poder-se utilizar estes compostos em novas estratégias como adjuvantes 
para o tratamento de células cancerígenas que apresentem características moleculares 
semelhantes às utilizadas neste estudo. 
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1. Cancer 
The term “cancer” originates from Greek physician Hippocrates, who noted the similarity 
between crabs and the cut surface of a solid tumor (Hajdu 2011). In medicine, the earliest 
report of cancerous diseases, refers to breast cancer, and dates back to, approximately, 3000 
B.C. However, paleopathological findings show that tumors existed in animals long before men 
appeared on Earth (Hajdu 2011).  
Our body is made up of trillions of living cells. Every cell has the ability to grow, divide 
and die in a well-ordered way. During the first years of a person’s life, the normal cells divide 
faster allowing the person to grow. Upon reaching adulthood, most cells divide only to replace 
worn-out or dying cells or to repair injuries. Normal cells become cancer cells as a result of 
alterations in cell DNA. If these alterations are not repaired and if they confer a survival 
advantage, the cell will not die as it should. Instead, the altered cells proliferate faster than 
normal cells and make new cells that the body does not need. Most types of cancer cells form 
a solid tumor (a mass), but in the case of leukemia, tumors are rare. In leukemia, neoplasia 
cells are mixed in blood and blood-forming organs (American Cancer Society, 2015). 
 
1.1. Cancer statistics 
According to worldwide GLOBOCAN estimates, produced by the International Agency 
for Research on Cancer (IARC) in 2012, there were 14.1 million new cases and 8.2 million 
deaths due to cancer (Ferlay et al. 2015). The overall data showed that lung and breast cancer 
are the most frequently diagnosed and caused the highest number of death in men and women, 
respectively in both developed and developing countries. In developed countries, colorectal 
and prostate cancer were also at the top of the list for the highest number of cases. The problem 
becomes more tragic in less developed countries where the cancer incidence has been 
increasing in the last decade and incurs lower survival rates, representing 57% of all cancer 
cases and 65% of cancer deaths worldwide (Sloan and Gelband 2007, Torre et al. 2015). 
Currently, cancer continues to be a worldwide killer disease, despite the large amount of 
research undertaken. By 2020, it is estimated that there will be a word population of 7.5 billion, 
with approximately 15 million of new cases of cancer and 12 million cancer deaths (Anand et 
al. 2008).  
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1.2.  Risk factors 
Several risk factors have been associated with the appearance of cancer. These include 
internal factors, which represent 5 - 10% of all cases (e.g. inherited mutations, hormones and 
immune conditions) and environmental/acquired factors, which represent 90 - 95% (e.g. 
smoking tobacco, alcohol consumption, lack of physical activity, bad eating habits, infectious 
agents, environmental pollution and radiation) (Figure 1) (Anand et al. 2008, Jemal et al. 2011). 
 
Figure 1 – The role of environmental factors in the development of cancer, with the percentage contribution of 
each factor. Adapted from Anand et al. (2008). 
 
Several agents from environmental or cellular (endogenous) sources are able to induce 
DNA damage directly, or in an indirect way that may contribute to mutagenesis (Loeb and Loeb 
2000, Helleday et al. 2014). As mentioned earlier, just 5-10% of all cancers are related with 
inherited gene defects, meaning that lifestyle factors have a great importance in cancer 
development. Changes in environmental and lifestyle factors seem a promising strategy for the 
prevention of cancer. There are some environmental factors that can promote the appearance 
of leukemia, such as viral infections, exposure to polycyclic aromatic hydrocarbons, pesticides, 
chlorinated drinking water, the presence also of nitrates in the water, radiation, usually from 
radioactive substances and ultraviolet (UV) light, and low-frequency electromagnetic fields 
(Belpomme et al. 2007). 
31% 
25% 
16% 
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1.3.  Cancer cell biology  
Cancer is a heterogeneous group of diseases, the main feature is the production of 
abnormal cells that grow beyond the natural boundaries. Nowadays, several hallmarks of 
cancer have been proposed, forming the fundamental principles of this malignant 
transformation. Tumor formation is a multistep process, where the normal cells evolve 
progressively into the neoplastic stage by acquiring particular capacities that enable them to 
become tumorigenic. These hallmarks are self-sufficiency in growth signals, insensitivity to 
antigrowth signals, genomic instability, avoiding apoptosis, limitless replicative potential, 
sustained angiogenesis, tissue invasion, metastasis, tumor-promoting inflammation, metabolic 
reprogramming, and evasion of the immune system (Hanahan and Weinberg 2011, Floor et al. 
2012). Each cancer has its own way of action. The following sections will highlight those 
characteristics particularly important for the development of leukemia, including genetic 
instability, proliferation and cell cycle arrest, and apoptosis.  
 
1.3.1. Genetic instability  
The greatest differences between cancerous and normal cells are their abilities to 
divide, survive, invade, metastasize and destroy the host. Genetic instability is one of the 
hallmarks found in cancer cells, including genetic changes such as mutations in specific genes 
and structural and numerical changes at the chromosomal level (Shen 2011). Mutations can 
appear due to DNA damage inflicted by environmental (e.g. radiations, industrial chemicals, 
natural carcinogens) or cellular sources (e.g. depurination, free radicals, DNA polymerase 
errors). In normal cells, DNA is replicated with high fidelity where the repair mechanisms are 
normally able to resolve the damage. However, due to the frequency of occurrence of DNA 
damage, the inaccessible structure of human chromatin and defects with DNA repair 
mechanisms, it is possible that some lesions escape the DNA repair mechanisms and produce 
mutations, contributing to genomic instability (Loeb and Loeb 2000, Lord and Ashworth 2012, 
Ferguson et al. 2015). Some of these changes will give the cell the capacity to ignore the 
regulatory processes needed to control cell division, expression, adaptation and even cell 
death, contributing to cancer initiation and progression. Besides that, this lack of stability 
generates cancer cells which are widely heterogenic, resulting in the development of cells 
resistant to certain chemotherapeutics (Loeb and Loeb 2000).  
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1.3.2. Proliferation and cell cycle   
The cell cycle is a process that allows the cell to grow, replicate its DNA and divide. It 
is divided into four sequential phases (as shown in Figure 2): S phase is when the DNA 
replicates, M phase is responsible for the cell division producing two daughter cells, and two 
gaps (G1 and G2). G1 appears after M phase, a time where the cell is responsive to positive 
and negative growth signals, and G2 follows S phase when the cell prepares to start mitosis. 
There is also a fifth state, G0 or quiescence, in the case of deprivation of the growth-promoting 
signals in the G1 gap (Garrett 2001, Williams and Stoeber 2012). 
The control of each phase and the transitions between them are controlled by sensor 
mechanisms. These monitor the cellular environment, mainly the genomic integrity, and 
determine if the cell must go on in the cell cycle progress. The main cell cycle checkpoints 
occur in the: G1/S phase transition, the biggest sensor of DNA damage; G2/M to monitor the 
fidelity of DNA replications and finally a mitotic checkpoint where the fidelity of chromosome 
segregation in mitosis is controlled (Garrett 2001). If some abnormality is detected, such as 
DNA damage, signaling pathways are activated resulting in cell cycle arrest in the attempt to 
“solve the problem” (Williams and Stoeber 2012). Mammalian cell cycle progression is 
controlled by cyclin-dependent kinases (Cdk), a family of serine/threonine kinases, through the 
phosphorylation of certain proteins (Garrett 2001). In the case of failure at cell cycle 
checkpoints, uncontrolled proliferation may occur - a typical characteristic for malignant 
phenotypes (Williams and Stoeber 2012). 
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Figure 2 – Cell cycle and respective checkpoints. Adapted from Garrett (2001). 
 
1.3.3. Apoptosis 
Apoptosis is a mechanism of programmed cell death that presents several 
morphological and biochemical modifications such as rounding-up of the cell, membrane 
blebbing, externalization of phosphatidylserine, mitochondrial fragmentation, protein cleavage, 
retraction of pseudopods, pyknosis (reduction of cellular volume), condensation of chromatin, 
karyorrhexis (nuclear fragmentation) and formation of apoptotic bodies, amongst others. It is 
important to consider that other types of programmed cell death exist and others may yet be 
discovered (Elmore 2007, Kroemer et al. 2009, Fuchs and Steller 2015).  
There are two main apoptotic pathways: the extrinsic or death receptor pathway and 
the intrinsic signals or mitochondrial pathway. The intrinsic pathway is initiated by several stress 
signals, such as radiation, drugs, free radicals, absence of growth factors, viral infections, 
amongst others that induce changes in mitochondrial permeability. Consequently, cause the 
release of cytochrome c, activation of caspase-9, -3 and other caspases that culminate with 
cell death (Kalimuthu and Se-Kwon 2013). The involvement of the Bcl-2 family proteins, 
responsible for mitochondrial outer membrane permeability, and the p53 tumor suppressor 
protein, which regulates the Bcl-2 proteins is crucial for the occurrence of this pathway. The 
Bcl-2 family includes anti- and pro- apoptotic proteins. The anti-apoptotic members are: Bcl-2, 
G1
S
G2
M
G2	Checkpoint	
G1/S	Checkpoint	
Go	
	
Mitotic	Checkpoint	
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Bcl-xL and Mcl-1 and the pro-apoptotic members are: Bax and Bak amongst others (Burke 
2010). In the extrinsic pathway, apoptosis is initiated by transmembrane receptor-mediated 
pathways, where cytokine ligands, such as TNF, bind to death receptors presents on cell 
surface, forming a death inducing signaling complex (DISC) that activates the caspase-8 and -
10, followed by the rest of the caspase cascade - once caspase-8 is activated, apoptosis is 
triggered. Disabling the apoptosis is one of the pathogenic occurrences which contributes to 
cancer initiation, promotion, and progression (Elmore 2007, Kalimuthu and Se-Kwon 2013). 
 
2. Leukemia  
Leukemia is one cancer that affects the blood-forming cells present in bone marrow and 
the hematopoietic process (Gibson et al. 2013). According to the GLOBOCAN project 2012, 
leukemia has a worldwide incidence of 351 965 cases which correspond to 2.5% of all cancers, 
and a mortality of 255 471 cases corresponding to 3.4% of all cancer deaths (Torre et al., 2015). 
This disease can affect the lymphoid or the myeloid stem cells, both resulting in the production 
of many white blood cells that are abnormal and do not mature normally (Vardiman et al. 2009). 
Referring to morphology, genetics, and clinical features, leukemia could be classified into four 
main groups: Acute lymphoid leukemia, chronic lymphoid leukemia, acute myeloid leukemia 
and chronic myeloid leukemia. In lymphoid leukemia, also known as lymphoblastic or 
lymphocytic leukemia, the abnormalities start in the cells that become lymphocytes. In myeloid 
leukemia, the cancer cells come from granulocytic, monocytic/ macrophagic, erythroid, 
megakaryocytic and mast cell lineages. The terms acute and chronic differ in the maturity of 
the leukemic cells (Vardiman et al. 2009).  
 
2.1. Chronic myeloid leukemia  
Chronic myeloid leukemia (CML) represents 15% of all cases of leukemia and the 
median age for this disease is 64 years (Gibson et al. 2013). The myeloid abnormally starts in 
the blood-forming cells of the bone marrow and is characterized by uncontrolled proliferation 
of neoplastic hematopoietic precursor cells and weakened production of normal hematopoiesis, 
causing several abnormalities in the blood such as neutropenia, anemia and thrombocytopenia 
(Ghosh et al. 2014).  
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CML can occur in two or three stages: the first one, known as chronic phase (CP), is 
normally asymptomatic and presents as a myeloid hyperplasia in the bone marrow and 
peripheral blood (< 20 %). The intermediate stage, called accelerated phase (AP), occurs with 
few symptoms. The second phase – the blast crisis (BC) – appears 3-5 years after diagnosis 
of untreated CML-CP patients, as a rapid progression, and the number of undifferentiated 
myeloblasts is higher than 20 %. In some cases the transition from CP into BC phase occurs 
without AP signals (O'Brien et al. 2009, Burke 2010, Jabbour and Kantarjian 2014). 
Some patients with CML have no symptoms at all, however, some of the symptoms 
commonly associated with this disease are the non-specifics (lethargy, fatigue, fevers, night 
sweats) or splenomegaly (such abdominal pain) (Gibson et al. 2013). Facing these symptoms, 
the main tests to diagnose this disease are a complete blood count (CBC) and bone marrow 
biopsy. Bone marrow cytogenetics is recommended to help choose the best treatment, taking 
into consideration the karyotypic abnormalities (O'Brien et al. 2009). 
 
2.1.1. Molecular approach  
Chronic myeloid leukemia is a hematopoietic stem cell disease which presents as a 
chromosome translocation between chromosomes 9 and 22 during cell division, resulting in a 
shorter chromosome 22 called Philadelphia chromosome. This translocation t(9;22)(q34;11) of 
DNA means that part of chromosome 22 breakpoint cluster region (BCR) gene at band q11 
fusion with chromosome 9 Abelson 1 (ABL) gene at band q34, leading to the formation of a 
new oncogene BCR-ABL (Rowley 1973). ABL is a proto-oncogene that encodes for a protein 
tyrosine kinase found mainly in the nucleus, which regulates the cell cycle, differentiation, 
migration, invasion, genomic instability and the response to genotoxic stress (Deininger et al. 
2000, Burke and Carroll 2010, Greuber et al. 2013). The BCR gene encodes for a 
serine/threonine kinase that can act as a GTPase-activating protein for members of the Rho 
family of guanine nucleotide exchange factors, and can also phosphorylate histones and casein 
(Burke 2010). 
BCR-ABL encodes a new protein, p210BCR-ABL which shows deregulated tyrosine kinase 
activity and contains the NH2-terminal domains of BCR and the COOH-terminal domains of 
ABL. The critical functional changes found with the expression of this new protein are: ABL 
protein becomes constitutively active as a protein tyrosine kinase enzyme; attenuation of DNA 
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protein-binding activity of ABL; and the improvement of the binding of ABL to cytoskeletal actin 
microfilaments (O'Brien et al. 2009). Animal models have confirmed that this protein plays a 
crucial role in the pathogenesis of CML, increasing cell proliferation, blocking apoptosis and 
stromal interactions of the cell. Hence, the development of targeted therapy with a specific 
action on tyrosine kinase was a breakthrough in the treatment of myeloid leukemia (Gibson et 
al. 2013). 
In very few cases, less than 10%, the leukemia cells present the BCR-ABL oncogene, 
but not the Philadelphia chromosome, and so it is possible that the BCR-ABL gene can be 
formed in a different way. There are also very rare cases where neither the oncogene nor the 
Philadelphia chromosome are found, which means that other oncogenes may be causing this 
disease (Onida et al. 2002). It is also possible to express another fusion protein (p190) however 
this is more common in cases of acute lymphoid leukemia (ALL) (O'Brien et al. 2009, Cutler et 
al. 2015). 
 
2.1.2. Downstream signaling pathways of BCR-ABL 
The BCR-ABL chimeric oncogene encodes for a constitutively active tyrosine kinase 
that modulates different signaling pathways, such as PI3K/AKT/mTOR, JAK-STAT, Wnt/β-
catenin and autophagy. This brings benefits in terms of cell survival, proliferation, differentiation, 
and migration, allowing cell proliferation, protection against cell death in the absence of external 
factors and promotion of invasion and metastasis (Sinclair et al. 2013). Modulation of survival 
pathways by BCR-ABL activation (Figure 3) has also been related to resistance to genotoxic 
therapeutics since BCR-ABL-positive cells can repair DNA damage more quickly through the 
up-regulation of RAD51 (a protein of homolog recombination repair system), decreasing its 
degradation and activating it through post-translational modification. The expression of RAD51 
in the cells seems to be positively correlated with the appearance of a resistance phenotype 
(Collis et al. 2001). The capacity to repair DNA is not only influenced by the efficiency of the 
repair mechanisms but also by the time that the cell has to carry out the mechanism. BCR-
ABL-positive cells are able to activate DNA damage-dependent cell cycle checkpoints faster 
by displaying a pronounced G2/M delay (Bedi et al. 1995). Another mechanism involved in drug 
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resistance is the modulation of Bcl-2 family members, namely the up-regulation of anti-
apoptotic proteins (e.g. Bcl-xl and Bcl-2) (Skorski 2002). 
 
2.2. Treatment of CML 
With advances in the knowledge of cancer biology, CML treatments have changed. 
Conventional chemotherapy treatment was widely used allowing the destruction of the cells. 
Examples of the drugs used in CML were busulfan followed by hydroxyurea. Both 
chemotherapeutics showed an improvement regarding the symptoms and hematology, but the 
cytogenetic remission was not significant (Henkes et al. 2008, Zhang et al. 2008). Allogeneic 
hematopoietic stem cell transplantation (HSCT) seems to be the type of treatment that proves 
Figure 3 – Mechanisms of drug resistance induced by BCR-ABL. In a normal cell (represented as black) DNA 
repair mechanisms are activated and DNA damage can be completely repaired – the cell will survive. In the case 
of inefficient repair, and if the cell cycle checkpoints are not strong enough to allow more time for repair, death 
signals are activated with induction of apoptosis. In a BCR-ABL expressed cell (represented as gray) the global 
levels of DNA repair mechanisms are increased. This also affects the checkpoints, providing more time for repair, 
however, the efficiency is compromised. In addition, in case of some unrepair or misrepair lesion escape, the 
apoptotic signals are inhibited by the regulation of Bcl-2 protein family. Overall, this process leads to an 
accumulation of DNA damage, increasing the genomic instability. Adapted from Skorski (2002). 
	Normal	cells	
	BCR-ABL	positive	cells	
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to cure more patients. Yet this method presents some disadvantages, such as the need for a 
suitable donor and the high toxicity of the procedure, which generates some side-effects such 
as immunodeficiency, infections, organ toxicity and graft versus host disease (Henkes et al. 
2008). Another treatment is the Interferon-α (IFN-α) therapy, introduced in the 1980s, this 
presents some positive final results regarding remission and disease-free survival. However, 
the toxicity levels in the patients proved to be a problem, because of their ability to induce 
fatigue, myalgias, arthralgias, headaches, weight loss, depression, diarrhea, neurological 
symptoms, memory changes, hair thinning, autoimmune diseases, and cardiomyopathy 
(Henkes et al. 2008, Burke 2010). The need to find more potent and specific agents combined 
with the better understanding of molecular mechanisms underlying CML led, in the early 1990s, 
to the development of tyrosine kinase inhibitors (e.g. imatinib). Imatinib results in the inhibition 
of proliferation, restoration of the cell cycle, apoptosis induction and reversal of genetic 
instability in BCR-ABL dependent cells. However, even with the exceptional efficiency of TKI, 
problems may occur, such as drug resistance, loss of response, kinase domain mutations and 
transformation of the disease (e.g. evolution to an accelerated or blast phase). The BC is 
typically lethal, at this point more aggressive treatments are applied such anthracyclines 
(O'Brien et al. 2009). The previous two treatments (TKI and anthracyclines) will now be 
explored in further detail. 
 
2.2.1. Tyrosine kinase inhibitors 
Nowadays, the first-line of treatment for myeloid leukemia in the chronic phase is 
imatinib mesylate (STI-571), a potent BCR-ABL tyrosine kinase inhibitor (TKI) (Druker et al. 
2006). TKI will bind competitively to the adenosine triphosphate (ATP) binding site of the BCR-
ABL protein and consequently inhibits the phosphorylation of proteins related to BCR-ABL 
signal transduction (Mahon et al. 2000, Gibson et al. 2013). The final outcome is the induction 
of apoptosis in hematopoietic cells expressing BCR-ABL without affecting normal cells (Druker 
et al. 1996). Imatinib proved to be an efficient treatment for myeloid leukemia since patients 
showed 85% of overall survival (Gibson et al. 2013). 
Despite the specific mechanisms of action, around 33% of patients started to fail to 
achieve a complete cytogenetic response (CCyR), either because of the toxicity or (mostly) due 
to the appearance of a resistant phenotype over time (O'Brien et al. 2009, Bhamidipati et al. 
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2013). The hematologic and nonhematologic toxicities caused by imatinib include neutropenia, 
thrombocytopenia, gastrointestinal disturbances, edema, skin rashes and musculoskeletal 
complaints (Gibson et al. 2013). Furthermore, some patients present, after a few years with 
imatinib treatment, signals of cardiotoxicity with congestive heart failure (CHF) (O'Brien et al. 
2009). This resistance may be due to a range of mechanisms, some are BCR-ABL-dependent 
and others are BCR-ABL-independent mechanisms. The BCR-ABL-dependent mechanisms 
include, most frequently, point mutations in the ABL tyrosine kinase domain (TKD) and gene 
amplification of ABL (Bhamidipati et al. 2013). An important mutation is one that results in the 
formation of amino acid substitutions in imatinib binding sites, frequently called “gatekeeper” 
mutations (e.g. T315I) (Gibson et al. 2013). The BCR-ABL-independent mechanisms of 
resistance involve: (1) decrease in drug uptake by expression of the human Organic Cation 
Transporter 1 (hOCT1) (Thomas et al. 2004); (2) improved drug efflux by overexpression of P-
glycoprotein (P-gp) efflux pumps, reducing the amount of intracellular drug (Mahon et al. 2000); 
(3) increase of plasma protein α1 acid glycoprotein (AGP), which binds to imatinib preventing 
the ABL kinase inhibition (Gambacorti-Passerini et al. 2000); (4) increase of prostaglandin-
endoperoxide synthase 1 (cyclooxygenase 1), which plays an important role in imatinib 
metabolism (Villuendas et al. 2006). 
In response to the emergence of imatinib resistance, the development of second-
generation TKI began. These include nilotinib (Tasigna TM) and dasatinib (Sprycel TM). Both 
drugs achieved positive molecular responses, even activing with imatinib-associated kinase 
domain mutations, yet each drug induced its own mutations, and neither could inhibit BCR-ABL 
T315I (Gibson et al. 2013, Zhou and Xu 2015). A mutation in the ATP phosphate-binding loop 
(P-loop) is associated with poor prognosis and a high risk for progression (O'Brien et al. 2009, 
Mughal et al. 2013). Other types of TKI are also in development, such bosutinib and ponatinib, 
the latter presenting activity against the T351I mutation (Gibson et al. 2013).  
 
 
 
2.2.1.1. Current strategies to enhance the therapeutic effect of imatinib 
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 Resistance development in leukemia cells and the potential toxicity have been great 
limitations for imatinib application (Hu et al. 2009). The future of CML therapy passes to the 
development of new potent agents, perhaps in combinations with existing treatments in lower 
doses. 
 Nimmanapalli et al. (2003) showed that imatinib, when combined with suberoylanilide 
hydroxamic acid (SAHA), known as an inhibitor of histone deacetylases, can enhance the 
cytotoxicity effects in leukemia cells (K562 cell line) by up-regulation of p21 and p27 and down-
regulation of BCR-ABL levels with induction of apoptosis in BCR-ABL-expressed cells. A 
decrease in phopho-AKT and Bcl-xL levels was also observed. After experiments in two CML 
murine models, Hu et al. (2009) concluded that a low dose of imatinib combined with 
bortezomib (proteasome inhibitor) or proteasome inhibitor might optimize the CML treatment. 
The results showed inhibition in Bcl-2, increase of cytochrome c and activation of caspases, 
along with inhibition of proteasomal degradation of protein phosphatase 2A (PP2A). The 
combination was proven to have an inhibitory effect on tyrosine kinase via suppression of 
NFκB. Lin et al. (2016) demonstrated that by down-regulating RanGTPase and activating 
protein 1 (RanGAP1) it is also possible to improve the imatinib efficiency because RanGAP1 
can mediate BCR-ABL nuclear entrapment to activate the P73-dependent apoptosis pathway. 
 
2.2.2. Anthracyclines 
Anthracyclines are one of the most effective classes of anti-tumor antibiotics used for 
the treatment of numerous cancers, including breast, ovarian (Bellarosa et al. 2001), prostate, 
lung (Pratesi et al. 1998), and leukemia, amongst others (Hehlmann 2012). One of the first 
anthracyclines to be isolated was doxorubicin, isolated from Streptomyces peucetius var. 
caesius in the 1960s (Malla et al. 2010). Despite the wide use of this drug, its mechanism of 
action is not completely understood. However, several studies demonstrated its involvement in 
the inhibition of DNA and RNA synthesis, in the inhibition of topoisomerase II with subsequent 
formation of DNA double-strand breaks and the induction of cell death (Laroche-Clary et al. 
2000, Park et al. 2005), and in the synthesis of free radicals (Lebrecht et al. 2004, Thorn et al. 
2011).  
Beside the broad anticancer activity, the action of doxorubicin has been related with 
several side effects such as non-targeted cytotoxicity and acquisition of multidrug resistance 
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(MDR) phenotype. In CML the main mechanisms that contribute for MDR involve the P-gp by 
sequestration of the drug into cytoplasmic vesicles, the expression of antiapoptotic protein Bcl-
2 and the gene BCR-ABL (Misra and Sahoo 2011). 
 
2.2.2.1. Current strategies to enhance the therapeutic effect of doxorubicin 
Referring to the limitations of doxorubicin, such as drug resistance of cancer cells and 
the side-effects on normal cells, several strategies have been made to overcome these 
problems. One possibility to potentiate the action of doxorubicin is to combine this drug with 
synthetic or natural agents (Ghosh et al. 2014). 
According to Misra and Sahoo (2011), the combination of doxorubicin with curcumin (a 
natural polyphenol) exhibited a synergistic inhibitory effect on growth of K562 cells. The 
synergistic growth inhibition was mediated through different mechanisms that involved the 
inhibition of p210BCR-ABL. The authors suggest that the synergistic effect is clinically important 
and may provide combinatorial strategies in cancer therapy. Jang et al. (2013) reported the 
synergetic effect of the combination treatment of decursin (a natural compound present in 
Angelica gigas) and doxorubicin, in multiple myeloma cells, by enhancing apoptotic activity via 
mTOR. Also observed was the activation of caspase -9 and -3, the cleavage of poly (ADP-
ribose) polymerase (PARP), increase of sub-G1 population, and decrease in the expression of 
cyclind-D1 and survivin amongst other effects in U266 cells. Ghosh et al. (2014) showed that 
extracts from the hot water in black tea have protective effects against chemotherapeutic drugs, 
such as daunorubicin (an anthracycline), in normal lymphocytes. This extract is able to inhibit 
drug-induced ROS generation and renew the mitochondrial membrane potential (MMP). It 
increases cellular viability, up-regulates endogenous antioxidants enzymes, inhibits mRNA 
expression of apoptotic genes, prevents caspase-3 activation and reduces DNA fragmentation. 
 
3. Seaweed as a source of bioactive compounds  
Several epidemiological studies have shown that some phytochemicals present in 
vegetables and fruits are able to reduce the risk of degenerative processes (Abubakar et al. 
2012, Anand et al. 2008, Kim et al. 2010, Rengarajan et al. 2013). Marine organisms are a rich 
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source of bioactive compounds with several biological activities, and the interest by the 
scientific community has grown rapidly. In particular, seaweed, as photosynthetic organisms, 
are exposed to high amounts of light and oxygen which favors the formations of free radicals 
and other oxidative reagents. However, the absence of any serious photodynamic damage 
means that marine algae have the ability to generate bioactive components to protect 
themselves (Heo et al., 2008).  
Marine algae can be divided into four main groups, according to the type of pigments, 
morphology, anatomy and reproductive structures: Chlorophyceae (green algae), Phaeophyceae 
(brown algae), Rhodophyceae (red algae) and Cyanophyceae (blue-green algae) (Kolanjinathan 
et al. 2014). Seaweed are multicellular eukaryotic and macroscopic organisms living in salty 
water and mostly belong to the green, brown and red algae. They have been integrated into the 
human diet in some countries, such as Japan, since ancient times. In line with such traditions, 
the consumption of this natural product around the world is increasing nowadays (Kolanjinathan 
et al. 2014). Seaweed are a rich source of polysaccharides, minerals, protein, vitamins, and low-
fat carbohydrate (Cornish and Garbary 2010). High levels of bioactive compounds can be 
produced by a variety of marine macro and microalgae which provide several properties such as 
antibacterial, antiviral, immunosuppressant, antioxidant, antiproliferative and antitumor activity 
(Sharif et al. 2014). 
The use of bioactive compounds in combination with conventional anticancer drugs is 
poorly explored but the strategy may improve the clinical performance in conventional 
chemotherapy by altering the biological disposition to minimize toxicity, maximize efficacy and 
possibly reduce the dose of therapy (Yamamoto et al. 2011, Ghosh et al. 2014).  
 
3.1. Carotenoids 
Seaweed pigments can be divided into three main groups: chlorophylls, carotenoids, 
and phycobiliproteins. Carotenoids, organic pigments found in chloroplasts and chromoplasts, 
exhibit a purple, red, orange and yellow color — actually, carotenoids are a class of tetraterpene 
pigments found in bacteria, fungi, algae, as well as in higher plants and animals (Chojnacka et 
al. 2012). Nowadays, more than 700 carotenoids have been found in nature (Dembitsky and 
Maoka 2007, Maoka 2011, Takaichi 2011). The intake of dietary carotenoids has been 
correlated with a lower incidence of cardiovascular and neurodegenerative diseases, cataract 
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formation and cancer (Barros et al. 2014, Saini et al. 2015).  Diverse biological functions such 
as provitamin A activity, antioxidant (quench singlet oxygen activity, scavenge free radicals), 
antiproliferative, and proapoptotic activity and enhancement of the immune system has been 
attributed to the carotenoids (Ishikawa et al. 2008, Fernández-García et al. 2012, Tanaka et al. 
2012). The antioxidant activity of carotenoids is related to their structure; the number of double 
bonds and the presence of functional groups influence their ability to interact with different 
radicals (Sachindra et al. 2007). 
 
3.1.1. Fucoxanthin 
Fucoxanthin is one of the most abundant carotenoids found in nature, particularly in 
marine environments. This xanthophyll represents more than 10% of the total carotenoid 
production. Fucoxanthin is widely distributed in brown algae (Phaeophyceae) and diatoms 
(Bacillariophyta) and has an unusual structure that includes an allenic bond and 5,6-
monoepoxide moiety (Figure 4) (Rengarajan et al. 2013). 
 
 
 
 
 
 
Fucoxanthin has preventive effects against several types of cancer, including leukemia, 
due to its mechanisms of action, which include antiproliferation, cell cycle arrest, apoptosis 
induction, and suppression of angiogenesis (Anand et al. 2008, Rengarajan et al. 2013, Wang 
et al. 2012). Furthermore, the anticancer effect of fucoxanthin seems to be in some cases 
specific for cancer cells without cytotoxic effects against normal cell lines (Ishikawa et al. 2008). 
In leukemia, the effects of fucoxanthin are poorly understood. Here we tried to summarize the 
current knowledge of the effects of fucoxanthin in leukemia. 
Figure 4 – Fucoxanthin structure. 
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3.1.2. Anticancer effect of fucoxanthin in leukemia 
In vitro and in vivo research has shown the anticancer effects of fucoxanthin in 
leukemia. Fucoxanthin and fucoxanthinol (its metabolite) decrease the viability of HTLV-1 
infected T-cell lines and ATL cells through the induction of G1 cell cycle arrest, associated with 
down-regulation of cyclin D1, cyclinD2, CDK4 and CDK6 expression, and up-regulation of 
GADD45α, which will inhibit the entry of cells into S phase (Ishikawa et al. 2008). These authors 
also showed induction of apoptosis with activation of caspase-3, -8 and -9, and down-regulation 
of antiapoptotic protein expression, such as XIAP, cIAP2, Bcl-2 and survivin. In mice, 
fucoxanthinol suppresses tumor growth without adverse effects (Ishikawa et al. 2008). 
Nakazawa et al. (2009) observed that fucoxanthin induces apoptosis in HL-60 leukemia 
cells and other cell lines with down-regulation of anti-apoptotic Bcl-2 proteins. Kim et al. (2010) 
also showed that the inhibitory growth of fucoxanthin in leukemia cell lines was due to apoptosis 
induction caused by the generation of ROS, along with the indication of cell cycle arrest in G1 
stage. However, Kotake-Nara et al. (2005) demonstrated that apoptotic activity of fucoxanthin 
in promyelocytic cell lines is not caused by ROS. Besides the antiproliferative and proapoptotic 
effects of fucoxanthin in HL-60 leukemia cells, Ganesan et al. (2011) showed the anti-
angiogenesis effects of fucoxanthin mediated by down-regulation of signal transduction by 
fibroblast growth factor 2 (FGF-2) and its receptor (FGFR-1) in human umbilical vein endothelial 
cells (Ganesan et al. 2013). However, information about the effects of fucoxanthin in CML is 
clearly missing. 
 
3.2. Phlorotannins 
Phlorotannins are tannin derivatives composed of phloroglucinol units linked to each 
other in different ways (Cornish and Garbary 2010, Thomas and Kim 2011). Phloroglucinol 
(1,3,5-trihydroxybenzene) is a phenolic compound isolated from Ecklonia cava that has three 
hydroxyl groups in the benzene ring (Figure 5). This class of polyphenols is unique in brown 
seaweed and several biological activities have been attributed to it, such as antioxidant, anti-
inflammatory, antibacterial, anti-allergic and anticancer properties (Pádua et al. 2015, Corona 
et al. 2016).  
	19	
	
 
 
 
 
Figure 5 – Phloroglucinol structure. 
 
3.2.1. Anticancer effect of phloroglucinol in leukemia 
Phloroglucinol has demonstrated cytoprotective effects in normal cells from the toxicity 
found in cancer treatments, proving to be a good candidate to improve the quality of these 
treatments. The protective effect in mice intestinal cells was accomplished by blocking the 
activation of p53, downregulation of Bax and Bak-dependent pathway and up-regulation of the 
levels of Bcl-2 and Bcl-XS/L (Ha et al. 2013). According to Kang et al. (2010), phloroglucinol 
efficiently protected cells against radiation and extended the survival of mice exposed to lethal 
doses of radiation through the inhibition of mitogen-activated protein kinase kinase-4 
(MKK4/SEK1), c-Jun NH2-terminal kinase (JNK), activator protein-1 (AP-1) cascades and 
protected the depletion of reduced glutathione. Phloroglucinol also has a protective effect 
against lipid peroxidation and DNA damage induced by radiation (Kang et al. 2010). 
Besides the cytoprotective effects in normal cells, phloroglucinol also showed cytotoxic 
effects against cancer cells. Such effects in leukemia cell lines are poorly explored, however, 
some studies showed in vitro antiproliferative activity of phloroglucinol and of its derivatives in 
a variety of cancer cell lines including K562 cells. According to Liu et al. (2011) hyperforin, an 
abundant phloroglucinol-type, induced, in K562 cells, the dissipation of mitochondrial 
transmembrane potential caused by radiation, through the release of cytochrome c. 
Phloroglucinol induced the activation of the caspase-3, -8 and -9 cascade and consequently 
PARP cleavage. Cell cycle arrest was also observed with the increased expression levels of 
both p53 and p27kip1. Quiney et al. (2006) presented the same results for other leukemia cells, 
e.g. B-cell chronic lymphocytic leukemia (B-CLL), where hyperforin induced apoptosis by 
disruption of the mitochondrial transmembrane potential, activation of caspase-3 and cleavage 
of the PARP. Furthermore, downregulation of Bcl-2 proteins, Mcl-1 (anti-apoptotic proteins) and 
nitric oxide (NO) synthase of type 2 were also observed. In this study, downregulation of the 
cell cycle inhibitor, p27kip1 was detected in contrast with the results from Liu et al. (2011). Using 
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chronic lymphocytic leukemia cells in ex vivo studies Merhi et al. (2012) showed that the 
mitochondrial pathway of caspase-dependent apoptosis was induced by up-regulation of Noxa 
(protein of Bcl-2 family). More studies are needed to properly understand the effects of 
phloroglucinol against leukemia and information about the effects in CML is clearly missing. 
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Objective 
 
The objective proposed for this work was to evaluate the anticancer activity of two 
natural compounds — fucoxanthin, a marine carotenoid, and phloroglucinol, a phenolic 
compound — in vitro, using two cancer cell lines (K562 and TK6 cells) derived from CML-BC. 
The anticancer effects were evaluated either alone or in co-incubation with IC30 of two 
anticancer drugs, to evaluate the ability of natural compounds to potentiate the existing cancer 
treatments. To accomplish this objective, the following assays were carried out: 
 
- Effects on cell viability: After an exposure time of 24 h, the cellular density was 
determined by cell counting using a Neubauer chamber. This technique allows us to 
determine the short-term effects of the desired treatments on the cells, in other words 
the cytotoxicity of the desired treatment. 
- Antiproliferative effects: After an exposure time of 24 h followed by a further 48 h in 
fresh medium, the cellular density was determined by cell counting using a Neubauer 
chamber. With this assay, it was possible to determine the ability of the cells to 
proliferate after short-term exposure to the desired treatments. The combinations that 
showed anticancer potential were selected for the next assays. 
- Induction of DNA damage: After 24 h of incubation with the selected conditions, comet 
assay with and without the incubation of FPG enzyme was performed to determine the 
FPG-sensitive sites and strand breaks, respectively.  
- Effects on cell death: After 48 h of treatment with the selected conditions, the nuclear 
condensation assay was performed to assess induction of cell death by apoptosis. 
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Abstract 
 
Aim: The anticancer effects of fucoxanthin (Fx) and phloroglucinol (Ph), alone or co-incubated 
with anticancer drugs, doxorubicin (Dox) and imatinib (Imat), were evaluated in two cancer cell 
lines (K562 and TK6) representative of CML-BC. 
Material and methods: To achieve this aim, cytotoxicity at short time (24 h), proliferation 
capability (24 h with treatment and a further 48 h in fresh medium) by cell counting using a 
Neubauer chamber, induction of DNA damage by comet assay, and induction of cell death by 
apoptosis observed by morphological changes, were evaluated in K562 and TK6 cancer cells. 
Results and conclusions: Doxorubicin decreased cell proliferation in both cell lines increasing 
oxidative DNA damage and nuclear condensation in TK6 cells. Imatinib also inhibited cell 
proliferation in K562 cells.  However, no effects were founded on DNA damage and nuclear 
condensation. Fucoxanthin demonstrated a decrease on cell proliferation without induction of 
DNA damage or nuclear condensation in both cell lines. In co-incubation increased the 
antiproliferative effects of both drugs in the cell lines tested, however no differences where 
obtained when compared the combinations with fucoxanthin alone. Phloroglucinol also 
presented anticancer capabilities, decreasing cell proliferation alone, and in co-incubation to 
potentiate imatinib action in TK6 cell lines, without induction of DNA damage or apoptosis 
levels. In conclusion, both natural compounds (fucoxanthin and phloroglucinol) exhibit 
antiproliferative effects in K562 (fucoxanthin) and TK6 (fucoxanthin and phloroglucinol) cells. 
When co-incubated with the drugs (doxorubicin and imatinib), fucoxanthin increased 
antiproliferative effects of doxorubicin (in K562 cells) and imatinib (in K562 and TK6 cells) while 
phloroglucinol increased the antiproliferative effects of imatinib mainly in TK6 cells. DNA 
damage or apoptosis seems not to be the main mechanisms behind the antiproliferative effects 
induced by fucoxanthin and phloroglucinol. 
Significance and impact of the study: The inclusion of the studied natural compounds with 
the existing treatments could promote significant advances for cancer treatment, such as 
enhancement of the applied treatments and minimize side-effects mainly in more advanced 
stages of the disease. The findings call for a deeper understanding of the molecular 
mechanisms underlying the effects of the studied compounds. 
 
Keywords: Doxorubicin · Fucoxanthin · Imatinib · Leukemia · Phloroglucinol 
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Abbreviations: Abelson murine leukemia (ABL); Accelerated phase (AP); Adenosine 
triphosphate (ATP); Alpha-1-acid glycoprotein (AGP); Blast crisis (BC); Breakpoint cluster 
region (BCR); Chronic phase (CP); Chronic myeloid leukemia (CML); 4’,6-diamidino-2-
phenylindole (DAPI); Dimethyl sulfoxide (DMSO); Doxorubicin (Dox); Fetal bovine serum 
(FBS); Formamidopyrimidine DNA glycosylase (FPG); Fucoxanthin (Fx); Human organic cation 
transporter 1 (hOCT1); Imatinib (Imat); Multidrug resistance (MDR); P-glycoprotein (P-gp); 
Paraformaldehyde (PFA); Phloroglucinol (Ph); Phosphate-binding loop (P-loop); Phosphate 
buffered saline (PBS); Roswell Park Memorial Institute Medium (RPMI); Tyrosine kinase 
inhibitors (TKI).
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1. Introduction 
 
Chronic myelogenous leukemia (CML) is a myeloproliferative disorder which accounts 
for 15-20% of all adult leukemias (Yin et al. 2004, Gu et al. 2012). CML is characterized by 
uncontrolled proliferation of myeloid cells in the bone marrow and blood (Ghosh et al. 2014). 
The genetic hallmark of CML is the Philadelphia chromosome, an abnormality acquired from a 
chromosome translocation t(9;22) q(34;q11), resulting in the generation of the BCR-ABL fusion 
oncogene (Rowley 1973, Burke and Carroll 2010). BCR-ABL has high tyrosine kinase activity 
disrupting signaling pathways that regulate cell proliferation, apoptosis, differentiation, 
adhesion and genomic stability (Skorski 2002, Druker 2008). CML treatment includes several 
conventional chemotherapeutic agents, such as busulfan and hydroxyurea, however the 
incomplete cytogenetic response and the side-effects may limit the use of this drug as a clinical 
treatment (Henkes et al. 2008). The need to develop more potent and specific agents using 
knowledge of the molecular mechanisms underlying CML lead to the development of tyrosine 
kinase inhibitors (TKI) (Zhang et al. 2008).  
Imatinib mesylate (Gleevec) is the first generation of BCR-ABL TKI that was clearly a 
great achievement for CML treatment, since this drug acts in a specific way, inhibiting the 
activity of BCR-ABL. Imatinib interacts with BCR-ABL adenosine triphosphate (ATP) binding 
sites and consequently inhibits the phosphorylation of proteins related with BCR-ABL signaling 
pathways (Mahon et al. 2000, Gibson et al. 2013). However, around 33% of patients have 
relapsed due to the appearance of a set of mutations, mainly T315I mutation, leading to the 
appearance of resistant phenotype overtime (O'Brien et al. 2009, Bhamidipati et al. 2013, 
Gibson et al. 2013). These mutations represented a new challenge for CML treatments, which 
promoted the development of the second generation of TKI, including nilotinib (Tasigna TM) and 
dasatinib (Sprycel TM), yet other mutations in the ATP phosphate-binding loop (P-loop) also 
occur (O'Brien et al. 2009). Alternative strategies to overcome the T315I mutation and 
effectively kill leukemia cells in a more advanced stage such as blast crisis are applied, for 
instance, anthracyclines (O'Brien et al. 2009). One of the first anthracyclines to be isolated was 
doxorubicin, isolated from Streptomyces peucetius var. caesius in the 1960s (Malla et al. 2010). 
The main mechanisms of action include: (i) inhibition of DNA and RNA synthesis; (ii) inhibition 
of topoisomerase II with subsequent formation of DNA double-strand breaks and induction of 
cell death; and (iii) free radical synthesis (Laroche-Clary et al. 2000, Lebrecht et al. 2004, Park 
et al. 2005, Thorn et al. 2011). However, the use of doxorubicin has been linked with some 
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adverse side-effects including cytotoxicity in normal cells (mainly in cardiomyocytes) and 
acquisition of multidrug resistance (MDR) phenotype. MDR is a multifactorial process amongst 
which the well-known are drug efflux and influx, drug detoxification, mechanisms of DNA repair 
and resistance to apoptosis, all contributing to chemotherapy failure (Misra and Sahoo 2011). 
Since ancient times, seaweed have played an important part in the diet in Asian 
countries, and in the last decades their use as a food underwent a great expansion in the 
western world as well. Seaweed are rich in minerals, vitamins, polyunsaturated fatty acids, 
polysaccharides, carotenoids and phenolic compounds (e.g. phlorotannis) (Cornish and 
Garbary 2010, Chojnacka et al. 2012, Mohamed et al. 2012). Due to the presence of a high 
content of bioactive molecules, several biological activities have been attributed to seaweed, 
namely antioxidant, anti-inflammatory, antiestrogenic, anticancer, antidiabetic, antiobesity, 
antihypertensive, and antihyperlipidemic activity, protections against neurodegenerative 
diseases, healing, antiviral, antifungal, antibacterial, and larvicide activity, amongst others 
(Mohamed et al. 2012, Fernandes et al. 2014, Kolanjinathan et al. 2014, Pádua et al. 2015). 
Fucoxanthin is one of the most abundant carotenoids found in the marine environment, 
representing more than 10% of the total carotenoid production, and it is widely distributed in 
brown algae (Phaeophyceae) and diatoms (Bacillariophyta) (Rengarajan et al. 2013). 
Fucoxanthin has preventive and therapeutic effects against several types of cancer due to its 
mechanisms of action, which include antiproliferation, cell cycle arrest, apoptosis induction and 
suppression of angiogenesis (Anand et al. 2008, Wang et al. 2012, Rengarajan et al. 2013). 
Furthermore, the anticancer effects of fucoxanthin seem to be, in some cases, specific for 
cancer cells without cytotoxic effects against normal cell lines (Ishikawa et al. 2008). 
Phloroglucinol (1,3,5-trihydroxybenzene), a phenolic compound present mainly in brown 
seaweed, has anticancer activity by acting as an antioxidant, antiproliferative, proapoptotic, 
antiangiogenic and antimetastatic agent (Pádua et al. 2015, Corona et al. 2016).  
Anticancer activity of seaweed extracts and isolated compounds has been reported in 
several studies. However, effects in CML and its interaction with the conventional anticancer 
drugs has been less explored. In the present study, we intended to analyze the in vitro 
anticancer effects of two seaweed compounds (fucoxanthin and phloroglucinol) in leukemia cell 
lines, either alone or in combination with two conventional chemotherapeutic drugs used in 
leukemia treatment (imatinib and doxorubicin). The search for natural compounds with 
biological activity, namely anticancer activity and/or improvement of the actions of drugs 
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against cancer cells, is a promising field that can improve several cancer treatments. In this 
quest, reducing the anticancer drugs’ cytotoxicity against normal cells is also a key target. 
 
2. Materials and methods 
 
2.1. Chemicals and reagents 
Roswell Park Memorial Institute medium (RPMI-1640), doxorubicin, imatinib, sodium 
pyruvate, sodium bicarbonate, N-(2-hydroxyethyl)piperazine-N’-(2-ethanesulfonic acid) 
(HEPES), penicillin/streptomycin, 4,6-diamidino-2-phenylindole (DAPI), fucoxanthin and 
phloroglucinol were obtained from Sigma-Aldrich (St. Louis, MO, USA). Fetal bovine serum 
(FBS) was acquired from Biochrom KG (Berlin, Germany). Dimethyl sulfoxide (DMSO) was 
bought from AMRESCO LLC (Solon, SO, USA) and RO 19-8022 was generously provided by 
Hoffmann-La Roche and FPG enzyme was obtained from NEW ENGLAND BIOLABS U.S.A. 
All other reagents and chemicals used were of analytical grade. 
Stock solutions of doxorubicin, imatinib, fucoxanthin, and phloroglucinol were prepared 
in DMSO and aliquots kept at -20 ºC. For the use in each experiment, compounds and drugs 
were diluted in fresh culture medium and the final concentration of DMSO in the medium was 
0.5% (v/v). Negative controls were subjected only to culture medium with 0.5% of DMSO (v/v), 
to assess the effect of the solvent. 
 
2.2. Cell cultures 
Two human cancer cell lines were used to perform all the assays. K562 cell line, derived 
from blood of a patient with chronic myeloid leukemia (CML) in terminal blast crisis, was 
purchased from Sigma-Aldrich (St. Louis, MO, USA), and TK6 cell line, a human-derived 
lymphoblastoid cell line, was acquired from the American Type Culture Collection (ATCC). Both 
cell lines were maintained as suspension cultures in RPMI-1640 supplemented with 10% FBS 
and 1% antibiotic solution (100 U/ml penicillin and 100 μg/ml streptomycin), 0.1 mM sodium 
pyruvate and 10 mM HEPES under an atmosphere of 5% CO2 at 37 ºC.  
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2.3. Cytotoxicity assay 
 An important initial step is the determination of the optimal cell density growth for each 
cell line to perform the following assays. For this, cells were plated at different densities 
between 1 x 104 cells/ml and 4 x 105 cells/ml. The cells were counted at 24, 48 and 72 h after 
plating, using the Neubauer chamber on an inverted contrast phase microscope (Olympus 
CKX41, Japan), mixing the cell suspension with trypan blue (1:1) to allow standard counting.  
To evaluate the cytotoxic effect of the anticancer drugs (imatinib and doxorubicin) alone, 
cells were plated, K562 (0.3 x 106 cells/ml) and TK6 (0.2 x 106 cells/ml), in 24-multiwell culture 
plates, and incubated with different concentrations of imatinib (0 - 10 µm) and doxorubicin (0 - 
1 µm). Twenty-four hours after plating, cells were counted as described previously and cell 
density determined. The results are expressed as the survival percentage of cell viability that 
was calculated taking into consideration that the negative control (treated with 0.5% DMSO) 
had a 100% of survival. 
For the combination assays, cells were plated as referred above and incubated with the 
drug at IC30 concentration (concentration that inhibits cell viability in 30%) combined with 
different concentrations of fucoxanthin (0 - 10 µm) or phloroglucinol (0 - 300 µm). The cell 
density was determined after 24 h, as already described. Cells treated solely with either drug 
or with fucoxanthin or with phloroglucinol were also tested. 
 
2.4. Antiproliferation assay 
To assess the proliferation effects, 100 µl of cell suspension provided from the 
cytotoxicity assay were centrifuged, to remove the treatment, and plated again in fresh medium 
for more 48 h. After the incubation time, the cells were counted and cell density calculated. The 
results are expressed in relative suspension growth (RSG) that was the ratio of the total 
suspension growth (TSG) of each condition and the TSG of the negative control (treated with 
0.5% DMSO). TSG corresponds to the ratio between the number of cells seeded and the 
number of cells at the end of the assay (Azqueta et al. 2013). 
Only the conditions that decreased cell proliferation according to the data obtained in 
the respective assays were selected for the following assays. 
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2.5. Comet assay  
To determine the genotoxic effect of the conditions selected, cells were plated – K562 
at 0.3 x 106 cells/ml and TK6 at 0.2 x 106 cells/ml – in 6-multiwell culture plates and incubated 
with the desired treatment at 37 °C in an incubator with 5% of CO2. After the incubation time 
(24 h), DNA damage (strand breaks and alkali-labile sites) was assessed by the alkaline version 
of the single-cell gel electrophoresis (SCGE) or comet assay (Collins et al. 2008, Ramos et al. 
2010). Briefly, cells were washed, centrifuged and the pellet suspended in 0.5% low melting 
point agarose at 37 °C. About 2×104 cells/gel were spread on a microscopic slide pre-coated 
with 1% normal melting point agarose. For each condition three slides (lysis, buffer F, and FPG) 
were performed and in each slide two duplicated gels. Slides were incubated in lysis solution 
(2.5 M NaCl, 100 mM Na2EDTA, 10 mM Tris Base, pH 10 plus 1% (v/v) Triton X-100) for 1 h at 
4 ºC. After lysis, the slides for buffer F and FPG were removed, washed three times with buffer 
F solution and then incubated with the respective solution (buffer F or FPG) for 30 min at 37 
°C. Followed by place all the slides (lysis, buffer F and FPG) in a horizontal electrophoresis 
chamber with electrophoresis buffer (300 mM NaOH, 1 mM Na2EDTA, pH >13), for 40 min at 
4 ºC, allowing the DNA to unwind. Then run electrical field was applied, 300 mA, 25 V (1 V/cm) 
for 20 min at 4 °C to draw the negatively charged DNA toward an anode. After the 
electrophoresis, slides were washed twice with PBS and distilled water, and at the end dried at 
room temperature overnight. 
As a positive control for oxidative damage both cell lines were exposed to the 
photosensitizer Ro 19-8022 at three concentrations (1, 3 and 9 µm) (Azqueta et al. 2013). The 
cells were seeded at 1 x 106 cells/ml and exposed for 5 min to Ro 19-8022 on ice under a 
halogen lamp (33 cm of distance). After the collection, cells of positive control were submitted 
at the same procedure that was mentioned above.  
For the analysis of the comet images, slides were stained with 30 µl of DAPI solution (1 
μg/ml), covered with coverslips and comets were visualized in a fluorescence microscope 
(Olympus IX71, Japan). At least fifty comets were captured randomly per gel. The percentage 
of tail intensity was measured using OpenComet software (Gyori et al. 2014). Three 
independent assays were performed with two replicates per condition. 
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2.6. Nuclear condensation 
To assess the involvement of cell death as a possible mechanism of anticancer activity, 
cells were plated in 24-multiwell culture plates – K562 at 0.3 x 106 cells/ml and TK6 at 0.2 x 106 
cells/ml – and incubated (alone or in co-incubation) with the previously selected test 
compounds. After 48 h of incubation, nuclear condensation was assessed by observation in 
the fluorescence microscope (Olympus IX 71, Japan). Briefly, cells were collected, washed, 
centrifuged, and fixed with 4% paraformaldehyde (w/v) for 20 min at 37 ºC, and then attached 
to a poly-L-Lysine-covered slide using a Cytospin Cytocentrifuge (Thermo Scientific, USA). 
Once dried, slides were incubated with DAPI (1 μg/ml) for nuclei staining. The percentage of 
cells with condensed nuclei was calculated from the ratio between cells with nuclear 
condensation and the total number of cells. At least 300 cells were counted per sample (Ramos 
el al. 2016. 
 
2.7. Statistical analysis  
Statistical analysis was performed using the GraphPad Prism 6.0 software (GraphPad 
Software, La Jolla, CA, USA), being the results expressed as mean ± standard deviation (SD) 
from at least 2 independent experiments. The results were evaluated using one-way or two-
way ANOVA to assess significant differences (p ≤ 0.05) between treatment conditions and the 
negative control, followed by a post hoc multiple comparisons using the Bonferroni’s test or 
Dunnett’s test as appropriate. The assumptions of normality and of homogeneity of variances 
were not tested due to the low “n”, but they were assumed to occur, in line with the cell culture 
responses as detected in many resembling published studies and with the general robustness 
of the parametric tests from departures of the basic assumptions (Rasch and Guiard 2004, 
Schmider et al. 2010, Mckillup 2011).  
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3. Results 
 
3.1. Effects of fucoxanthin and phloroglucinol alone and in co-incubation 
with doxorubicin or imatinib on cell viability in leukemia cell lines 
 
In vitro anticancer effects of fucoxanthin and phloroglucinol, alone or in combination 
with anticancer drugs (doxorubicin or imatinib), in two cancer cell lines (K562 and TK6 cells) 
representative of CML-BC were tested. First, the optimal growth density for each cell line was 
determined by a density assay. The results showed that the optimal density for K562 cells was 
0.3 x 106 cells/ml and for TK6 was 0.2 x 106 cells/ml. All the followed assays were performing 
using the optimal density growth. Two different assays were performed the cytotoxic assay and 
the proliferation assay. The cytotoxic assay was used to determine the ability of the applied 
treatment to kill the cells in the short-term, and the proliferation assay was used to determine 
the ability of the cells, after treatment removal, to recover the damage and proliferate. Initially 
both cell lines were incubated with different concentrations of doxorubicin or imatinib to 
determine the IC30 for each cell line based on the results from the proliferation assay. The 
anticancer effects of fucoxanthin and phloroglucinol were evaluated either alone or in co-
incubation with IC30 for each drug, to assess their ability to potentiate the effects of the 
anticancer drugs tested.  
 
Effects of imatinib and doxorubicin on cell viability and proliferation in leukemia cell lines  
To assess cytotoxic effects of doxorubicin (0-1 µm) and imatinib (0-10 µm), K562 and 
TK6 cell lines were incubated for 24 h with each drug. Cell viability was significantly reduced in 
both cell lines when treated with doxorubicin in a dose-dependent manner. The decrease of 
cell viability was more pronounced in TK6 cell line with an inhibition of 87% at 1 µm (Figure 1c). 
Doxorubicin at all tested concentrations showed a significant cytotoxicity in TK6 cells. Imatinib 
alone, at the tested conditions, did not affect cell viability in both cell lines. 
Inhibition of cell proliferation was determined after 24 h of treatment, as in cytotoxic 
assay, followed by 48 h in new and fresh medium. The results showed that in K562 cell line, 
both drugs (doxorubicin and imatinib) inhibit the cellular growth, being almost 100% in the 
highest concentration tested (Figure 2a and b). Regarding TK6 cell line, doxorubicin clearly 
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showed to be more efficient, reaching 100% of inhibition with 0.01 µm of doxorubicin (Figure 
2c), while imatinib did not show any inhibitory effect (Figure 2d). IC30 values of doxorubicin and 
imatinib alone for each cell line were determined using the data from the proliferation assay to 
perform the co-incubation assays with the natural compounds (fucoxanthin and phloroglucinol). 
 
 
a) K562  b) K562 
c) TK6 d) TK6 
Figure 1 – Dose-response effects on cell survival, after 24 h of incubation with (a) doxorubicin (Dox), (b) imatinib 
(Imat), in K562 cell line, (c) Dox and (d) Imat, in TK6 cell line, evaluated by cell counting with a Neubauer chamber. 
Results are expressed as mean ± standard deviation (SD) of at least four independent experiments. Significant 
differences (* p ≤ 0.05; ** p ≤ 0.01; **** p ≤ 0.0001), when compared with those of the control, were tested by one-
way ANOVA, followed by post-hoc Dunnett’s tests.  
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Effects of fucoxanthin and phloroglucinol alone or combined with imatinib / doxorubicin 
on cell viability and proliferation in leukemia cell lines 
Cells were incubated with fucoxanthin (0-10 µm) or phloroglucinol (0-300 µm) alone and 
in combination with IC30 of doxorubicin or imatinib for 24 h (cytotoxic assay). The results 
showed that fucoxanthin at 10 µm alone inhibits cell viability by 30% but only in K562 cells 
(Figure 3a). In TK6 cell line, fucoxanthin did not induce cytotoxic effects when compared with 
the respective control (Figure 3c and d). In combination, fucoxanthin did not potentiate the 
b) K562 
c) TK6 
a) K562 
Figure 2 – Dose-response effects on cell proliferation via Relative Suspension Growth (RSG), after 24 h of 
incubation plus 48 h in new medium with (a) doxorubicin (Dox) and (b) imatinib (Imat), in K562 cell line; (c) dox 
and (d) imat in TK6 cell line, evaluated by cell counting with a Neubauer chamber. Results are expressed as 
mean ± standard deviation (SD) of at least four independent experiments. Significant differences (*** p ≤ 0.001; 
**** p ≤ 0.0001) when compared with the control were tested by one-way ANOVA, followed by post-hoc Dunnett’s 
tests.  
d) TK6 
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cytotoxic activity of both drugs in the cell lines tested. An exception was the combination (10 
µm Fx + 0.05 µm Imat) in K562 cells that significantly decreases cell viability by 29% when 
compared with imatinib alone, but there are no differences when related with fucoxanthin alone 
(Figure 3b). 
 
 
Phloroglucinol alone, at the conditions tested, did not affect cell viability of both cell 
lines. Also, the combination of phloroglucinol with doxorubicin or imatinib did not increase the 
cytotoxicity of the drugs in the tested cell lines (Figure 4).  
b) K562 a) K562 
c) TK6 d) TK6 
Figure 3 - Effect of fucoxanthin (Fx) alone (black bars) or in combination (gray bars) with doxorubicin (Dox) and 
imatinib (Imat) (at IC30) on cell cytotoxicity after 24 h of treatment and assessed by cell counting. Fx combined with 
(a) Dox or (b) Imat in K562 cell line; Fx combined with (c) Dox or (d) Imat in TK6 cell line. Results are expressed 
as mean ± standard deviation (SD) of at least four independent experiments. Significant differences (* p ≤ 0.05) 
among groups per situation of exposure were tested by two-way ANOVA, followed by post-hoc Bonferroni multiple 
comparison test. Percentages in brackets showed the decrease on cell viability in relation to respective control. 
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Attending to the results from the proliferation assay, in general, the inhibitory effects 
were more evident than in the cytotoxic assay. Fucoxanthin, in both cell lines, decreased cell 
proliferation, showing an inhibition around 50% for the highest concentration tested (10 µm) for 
both cell lines (Figure 5). In combination, fucoxanthin at 10 µm increased the antiproliferative 
effects of doxorubicin and imatinib in 36% and 55%, respectively, in K562 cells (Figure 5a and 
b). In TK6 cell line, only the co-incubation of 10 µm Fx with imatinib potentiated the 
antiproliferative effects of the drug by 41%, when compared with the drug alone. However, no 
significant differences were obtained when compared with the fucoxanthin alone in both cell 
lines tested. The combination 0.1 µm Fx + 10 µm Imat inhibited cell proliferation of TK6 cells in 
48% when compared with fucoxanthin alone but did not show differences regarding the drug 
alone (Figure 5d).  
c) TK6 
b) K562 
d) TK6 
a) K562 
Figure 4 - Effect of phloroglucinol (Ph) alone (black bars) or in combination (gray bars) with doxorubicin (Dox) and 
imatinib (Imat) (at IC30) on cell cytotoxicity after 24 h of treatment and assessed by cell counting. Ph combined with 
(a) Dox or (b) Imat in K562 cell line; Ph combined with (c) Dox or (d) Imat in TK6 cell line. Results are expressed as 
mean ± standard deviation (SD) of at least four independent experiments. 
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Phloroglucinol alone did not show any significant decrease in cell proliferation in K562 
cells (Figure 6a). In co-incubation, only (300 µm Ph + 0.05 µm Imat) decreased cell proliferation 
by 34% when compared with imatinib alone (Figure 6b). In TK6 cells, phloroglucinol caused a 
decrease in cell proliferation in a dose-dependent manner reaching, at the highest 
concentration (300 µm of Ph), around 60% of inhibition when compared with the respective 
control. In combination with doxorubicin, phloroglucinol did not affect cell proliferation in TK6 
cells. However, a significant increase of the proliferation capability (46%) was observed in the 
combination (50 µm Ph + 0.0004 µm Dox) when compared with phloroglucinol alone (Figure 
6c). Contrary, the combination of phloroglucinol with imatinib in TK6 cells at 50 and 300 µm 
significantly decreased cell proliferation when compared with imatinib alone, 28% and 44%, 
respectively. The inhibition induced by the combination 50 µm of Ph + Imat was also 
a) K562 b) K562 
c) TK6 d) TK6 
Figure 5 - Effect of fucoxanthin (Fx) alone (black bars) or in combination (gray bars) with doxorubicin (Dox) and 
imatinib (Imat) (at IC30) on cell proliferation via Relative Suspension Growth (RSG) after 24 h of treatment plus 48 h 
in new medium, assessed by cell counting. Fx combined with (a) Dox or (b) Imat in K562 cell line; Fx combined with 
(c) Dox or (d) Imat in TK6 cell line. Results are expressed as mean ± standard deviation (SD) of at least four 
independent experiments. Significant differences (* p ≤ 0.05; *** p ≤ 0.001) among groups per situation of exposure 
were tested by two-way ANOVA, followed by post-hoc Bonferroni multiple comparison test. Percentages in brackets 
showed the decrease on cell proliferation in relation to respective control. 
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significantly different when compared with phloroglucinol alone at the same concentration 
(Figure 6d). In resume, phloroglucinol seems to potentiate the antiproliferative activity of 
imatinib in TK6 cells.	 
 
 
 
The antiproliferative effects of fucoxanthin and phloroglucinol alone or in co-incubation 
with anticancer drugs (doxorubicin and imatinib) were confirmed in some combinations by the 
decrease of cell density and by alterations in cell morphology using a phase contrast 
microscope (data not shown) in K562 and TK6 cell lines. To evaluate the specific mechanisms 
behind these antiproliferative effects, some conditions that showed statistically significant 
differences when compared with the controls were selected for the following assays. 
a) K562 b) K562 
c) TK6 d) TK6 
Figure 6 - Effect of phloroglucinol (Ph) alone (black bars) or in combination (gray bars) with doxorubicin (Dox) and 
imatinib (Imat) (at IC30) on cell proliferation via Relative Suspension Growth (RSG) after 24 h of treatment plus 48 h 
in new medium, assessed by cell counting. Ph combined with (a) Dox or (b) Imat in K562 cell line; Ph combined with 
(c) Dox or (d) Imat in TK6 cell line. Results are expressed as mean ± standard deviation (SD) of at least four 
independent experiments. Significant differences (* p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001) among 
groups per situation of exposure were tested by two-way ANOVA, followed by post-hoc Bonferroni multiple 
comparison test. Percentages in brackets show the decrease or increase on cell proliferation in relation to respective 
control. 
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3.2. Effects of fucoxanthin and phloroglucinol alone and in co-incubation 
with doxorubicin and imatinib on DNA damage by comet assay in 
leukemia cell lines 
 
To assess the genotoxic effects of the natural compounds alone or in combination with 
these drugs, cells were incubated with selected conditions for 24 h and DNA damage (strand 
breaks and the FPG-sensitive sites) assessed by alkaline comet assay. 
As a positive control, K562 and TK6 cell lines were exposed to oxidative stress-inducing 
photosensitizer Ro 19-8022 and an increase in the DNA damage recognized by FPG was 
observed in all the concentrations tested (data not shown). In relation to the selected conditions, 
the results showed that none of the tested conditions increased the DNA damage detected by 
comet assay in K562 cells (Figure 7a). In TK6 cells, only doxorubicin significantly increased 
DNA damage recognized by FPG, with an increase of 16% in relation to the negative control 
(cells treated with 0.5% DMSO). These are preliminary results since it was not possible to 
quantify all the data from the comet assay. 
  
1	 2	
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 a) K562 b) TK6 
Figure 7 – Effect of natural compounds, fucoxanthin (Fx) and/or phloroglucinol (Ph) alone or in combination with 
doxorubicin (Dox) or imatinib (Imat) on DNA damage (strand breaks – SBs; FPG-sensitive sites) after 24 h in (a) 
K562 cell line and (b) TK6 cell line, assessed by comet assay, (c) Images from comet assay in TK6 cell line: 1 – SBs 
of negative control; 2 – FPG-sensitive sites of positive control; and 3 – SBs and 4 – FPG-sensitive sites in 0.0004 
µm of Dox. Results are expressed as mean ± standard deviation (SD) of at least two independent experiments. 
Significant differences (*** p ≤ 0.001) among groups per situation of exposure were tested by one-way ANOVA, 
followed by post-hoc Bonferroni multiple comparison test. Percentages in brackets show the increase in relation to 
respective control. In the case of K562 cells, the results are exploratory as they correspond at only one independent 
experiment (ongoing work). Scale bar – 100 µm. 
c) TK6 
1 2 
3 4 
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3.3. Effects of fucoxanthin and phloroglucinol alone and in co-incubation 
with doxorubicin on cell death by nuclear condensation in leukemia cell 
lines 
 
To evaluate if the inhibition of cell proliferation was caused by induction of cell death, 
the cells (K562 and TK6) were incubated, with the conditions previously selected, for 48 h and 
nuclear chromatin condensation was performed. As shown in Figure 8a, none of the 
experimental conditions tested increased the percentage of condensed nuclei in K562 cells. In 
TK6 cell line, only 0.0004 µm of doxorubicin induced an increase of 10% in the condensed 
nuclei when compared with the control. Fucoxanthin at 10 µm in combination with doxorubicin 
significantly decreased the condensed nuclei by 14% when compared with doxorubicin (Figure 
8b). Phloroglucinol was tested only in TK6 cell line and the results did not show any significant 
increase in the percentage of condensed nuclei (Figure 8c). 
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4. Discussion 
CML is a myeloproliferative disorder characterized by the presence of a new gene 
(BCR-ABL). Imatinib, a specific inhibitor of BCR-ABL protein kinase, is the first line of treatment 
for CML-CP, and has a great efficacy (Druke et al. 2006). However, in advanced stages of the 
disease (CML-BC) more aggressive treatments are applied. The search for new effective 
therapies with less side-effects are needed. 
Marine organisms are a rich source of bioactive compounds with several biological 
activities (Cornish and Garbary 2010, Sharif et al. 2014). Previous studies demonstrated that 
fucoxanthin, the most abundant marine carotenoid, and phloroglucinol, a phlorotannin, have in 
vitro cytotoxic effects against cancer cell lines (Kim et al. 2005, Kotake-Nara et al. 2005, 
Ganesan et al. 2011, Liu et al. 2011). The current work addresses – to our knowledge for the 
a) K562 
c) TK6 
b) TK6 
Figure 8 – Effect of fucoxanthin alone or co-incubated with doxorubicin (Dox) or imatinib (Imat) (IC30) on the 
induction of nuclear chromatin condensation in (a) K562 cell line and (b) TK6 cell line, and (c) phloroglucinol (Ph) in 
TK6 cell line, evaluated by the nuclear condensation assay after 48 h of incubation. Results are expressed as mean 
± standard deviation (SD) of at least four independent experiments.  
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first time – the in vitro anticancer activity of fucoxanthin and phloroglucinol alone or co-
incubated with anticancer drugs (imatinib and doxorubicin) in two human cancer cell lines 
representative of more advanced stages of CML (K562 and TK6 cell lines). For this, (i) short 
time cytotoxicity; (ii) proliferation capability; (iii) DNA damage induction; and (iv) cell death 
induction by apoptosis, were evaluated.  
Our results showed that doxorubicin seems to be more effective than imatinib in 
decrease cell viability and proliferation since it caused inhibitory effects at lower concentrations 
in both cell lines. However, imatinib proved to be more specific to K562 cell line, as expected. 
The efforts to eliminate cancer cells requires the knowledge of the cellular responses that are 
induced by anticancer drugs. Imatinib, a TKI, allows a faster reduction of BCR-ABL transcript 
levels when compared with doxorubicin which has a large range of cellular targets (Czyz et al. 
2008, Hanfstein et al. 2012, Minotti et al. 2004, Zhou and Xu 2015). Furthermore, the 
understanding of the characteristics of each cell line is also an important point. K562 cells are 
derived from a patient in blast crisis, being normally used as a cellular model for advanced 
stage of CML to investigate the cellular response to cytotoxic drugs. While TK6 cells were 
established from a patient with T-cell lineage blast crisis of CML and further complicated by 
hypercalcemia (Watanabe et al. 1995, Naumann et al. 2001).  
In a general way, the inhibitions obtained in the proliferation assay are higher than in 
the cytotoxic assay, which could mean that the effects are not related with direct cytotoxicity of 
the compounds, but are mediated by effects on different signaling pathways. Fucoxanthin 
decreased cell viability (in K562 cells) and proliferation in both cell lines tested. When co-
incubated with doxorubicin at IC30, fucoxanthin did not affect cell viability of both cell lines. 
However, the co-incubation with imatinib increased the cytotoxic effect of imatinib in K562 cells. 
In co-incubation, fucoxanthin plus doxorubicin or imatinib inhibited cell proliferation in K562 
cells. In TK6 cells, only fucoxanthin plus imatinib decreased cell proliferation when in 
combination. However, no significant differences were obtained when compared with the 
inhibition caused by fucoxanthin alone. Previous studies reported the antiproliferative effects 
of fucoxanthin on other leukemia cell lines, such as the HL-60 (Kotake-Nara et al. 2005, 
Ganesan et al. 2011). Furthermore, Ishikawa et al. (2008) reported that fucoxanthin was not 
cytotoxic to normal peripheral blood mononuclear cells supporting the specificity action of this 
natural compound on cancer cell lines. 
Phloroglucinol showed ability to decrease cell proliferation only in TK6 cell line, starting 
to induce a slight inhibition of proliferation at 50 µm and reaches 50% of inhibition with the 
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highest concentration (300 µm). In co-incubation with doxorubicin (at IC30) the proliferation was 
not affected, however, one condition revealed an increase of cell proliferation (e.g. 50 µm Ph + 
0.0004 µm Dox in TK6 cells). The same results were observed in our laboratory by other 
colleges, where phloroglucinol at low concentrations seems to protect cancer cell lines (HT-29 
and HCT116). Contrary, the combination of phloroglucinol with imatinib showed a great 
potential in TK6 cells. In this vein, the potentiation of the antiproliferative effects of imatinib was 
higher in TK6 cells, reaching almost 75% of inhibition when compared with control (cells treated 
with 0.5% DMSO). These data are in line with other studies that reported antiproliferative effects 
of phloroglucinol in several cell lines (Hostanska et al. 2003, Liu et al. 2011, Sun et al. 2011, 
Wijesinghe et al. 2013). The antiproliferative effects of fucoxanthin and phloroglucinol alone or 
in co-incubation with doxorubicin and imatinib were confirmed in this study in some 
combinations, either by the reduction of cell density or by alterations in cell morphology.  
The decrease in cell proliferation could be due to several mechanisms, such as increase 
of cell death and/or delayed mitosis. In the present work, we showed that decrease of cell 
proliferation induced by doxorubicin could be partially due to induction of cell death by apoptosis 
in TK6 cells; because a slight increase of nuclear condensation was observed. However, 
induction of apoptosis seems not to be the main mechanism behind the antiproliferative effect. 
In K562 cells, inhibition of cell proliferation induced by doxorubicin was not related with changes 
in the percentage of cells with nuclear condensation suggesting induction of other pathways. 
Different values of nuclear condensation between cell lines can be explained by the lack of a 
functional p53 protein observed in K562 cell line, which allow them to be more resistant to 
apoptosis, while TK6 cells express a stable p53 (Kuzelova et al. 2005, Schwartz et al. 2004). 
Other studies reported the same results, and the apoptosis reluctance, in both cell lines, can 
be explained due to the presence of deregulated tyrosine kinase activity of BCR-ABL protein. 
BCR-ABL protein phosphorylates substrate proteins which stimulate several signal 
transduction pathways (such as Ras, STAT5 and PI-3k) resulting in the increase of proliferation 
rate and resistance to apoptosis (Kuzelova et al., 2005, Laroche-Clary et al. 2000, Watanabe 
et al. 1995). Even using imatinib, that inhibits BCR-ABL kinase activity, the inhibition may not 
have been complete, as so low levels of activity allowed cells to survive but not proliferate 
(Druker et al. 2006).  Others mechanisms that have been described, could explain the low 
levels of apoptosis in the tested cell lines, such as BCR-ABL gene amplification and mutations, 
increase of drug efflux by overexpression of the multidrug resistant P-glycoprotein (P-gp) and 
low activity of drug influx transporter (hOCT1). In particular to imatinib, the apoptosis resistance 
could be also influenced by the increase of plasma protein α1 acid glycoprotein (AGP) that 
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inhibit imatinib action, and the prostaglandin-endoperoxide synthase 1 involved in imatinib 
metabolism (Apperley 2015, Druker et al. 2006, Gambacorti-Passerini et al. 2000, Mahon et al. 
2000, Villuendas et al. 2006). Czyz and collaborators demonstrated the induction of other 
pathways, such as senescence or differentiation by doxorubicin and imatinib in leukemic cells 
(Czyz et al. 2008).  
Our results suggest that the antiproliferative effect of fucoxanthin and phloroglucinol 
seems to be not related to induction of cell death since no significant increase of nuclear 
condensation was observed in both cell lines. However, fucoxanthin at 10 µm when co-
incubated with doxorubicin in TK6 cell line decreased the levels of nuclear condensation when 
compared with the drug alone. Ganesan et al. (2011) also reported low levels of apoptosis 
induced by fucoxanthin, which can indicate that the reduction in cell viability can be due to other 
mechanisms. Ishikawa et al. (2008) showed the ability of fucoxanthin to induce cell cycle arrest 
but also apoptosis, in agreement with other authors that reported the ability of fucoxanthin to 
induce apoptosis in leukemia cell lines, in opposite to our results (Kotake-Nara et al. 2005, Kim 
et al. 2010). An important characteristic of fucoxanthin to have in consideration for further 
utilization in cancer therapy is their ability to protect normal cell lines by inhibiton of DNA 
damage and apoptosis (Heo et al. 2008). Regarding phloroglucinol, no significant changes 
were observed in the nuclear condensation when cells were treated with the selected 
combinations. In opposition to our results, induction of apoptosis by phloroglucinol in leukemia 
cell lines was reported by other authors (Hostanska et al. 2003, Liu et al. 2011, Sun et al. 2011). 
As already noted by other authors and the same was found in our work, apoptosis induction 
was not the major mechanism for the reduction in cell proliferation after exposure to doxorubicin 
or imatinib (IC30) alone or in combination with the natural compounds (Castañeda et al. 2012). 
However, the analysis of nuclear condensation after longer incubation periods and other 
assays, such as TUNEL, Annexin V, cytochrome release or measure the levels of caspases, 
are needed to verify the induction of apoptosis. Other mechanisms such as cell cycle arrest or 
another type of cell death could be involved in the antiproliferative effects of the tested 
compounds and should be evaluated.  
DNA damage was assessed here since chemotherapeutics are known to induce it. DNA 
damage if not correctly repaired will accumulate in the cell and can cause either cell cycle arrest 
or apoptotic cell death (Bellarosa et al. 2001, Abubakar et al. 2012). Regarding our preliminary 
results, in K562 cell line none of the tested compounds induced DNA damage recognized by 
comet assay. In TK6 cell line, DNA strand breaks remained very low after cell exposure at 
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selected conditions. These results are supported by the presence of deregulated tyrosine 
kinase activity of BCR-ABL protein, as explained before, some pathways such as STAT5 can 
enhance the global levels of DNA repair mechanisms. However, doxorubicin in the tested 
conditions proved to be able to increase DNA damage recognized by FPG enzyme (recognize 
oxidative damage). Other authors already reported that, doxorubicin (Ferreira et al. 2007, 
Manjanatha et al. 2014) and imatinib (Koptyra et al. 2006) can increase FPG-sensitive sites in 
different cell types. Our preliminary results seem to indicate that doxorubicin can induce 
oxidative DNA damage that could culminate in a decrease of cell proliferation. This was an 
expected effect because the anticancer activity of many chemotherapeutic drugs is mainly due 
to their ability to induce DNA damage (Skorski 2002). However, the precise response to DNA 
damage should be further assessed. 
In conclusion, the results presented here indicate that both natural compounds alone 
showed antiproliferative effects against K562 (fucoxanthin) and TK6 (fucoxanthin and 
phloroglucinol) cells. Fucoxanthin increased the cytotoxic effects of doxorubicin (in K562 cells) 
and imatinib in both cells lines. However, this enhancement seems to be due to fucoxanthin 
alone and not due to the combination with the drug. Phloroglucinol increases the 
antiproliferative effects of imatinib in both cell lines but with more extension in TK6 cells. In this 
study, the antiproliferative effects of both compounds seem not to be due to cell death caused 
by apoptosis. However, more research is needed to confirm our results and to demonstrate the 
real potential of fucoxanthin and phloroglucinol against the cell lines tested. 
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Conclusions and future perspectives	
	
 The purpose of this study was to evaluate the anticancer activity of two natural 
compounds present in seaweed – fucoxanthin and phloroglucinol – alone or in combination with 
anticancer drugs (doxorubicin and imatinib), on two human cancer cell lines (K562 and TK6 cells) 
representative of CML-BC. 
 In vitro anticancer activity was evaluated by the decrease of cell viability and cell 
proliferation after a short-term exposure when compared with negative control (cells treated 
with 0.5% DMSO). Our results showed, as expected, that doxorubicin is more effective in the 
decrease of cell viability when compared with imatinib in both cell lines. K562 cells proliferation 
were affected in the same way by both drugs, yet TK6 cells proliferation was inhibited only by 
doxorubicin. Our study confirmed the specificity of imatinib to K562 cell line that can be 
explained by the specific mechanism of action of imatinib which binds to BCR-ABL specific-
sites. Different genetic characteristics are reported in the literature for each cell line, which 
could explain the differences attained in the results. Analyzing the data obtained by the natural 
compounds, fucoxanthin alone decreases cell viability in K562 and proliferation in both cell 
lines at 10 µm. In co-incubation with doxorubicin or imatinib (at IC30), fucoxanthin enhances the 
antiproliferative effects of the drugs in both cell lines. Phloroglucinol alone did not induce direct 
cytotoxicity at short term neither when co-incubated with the drugs. Cell proliferation seems to 
be affected by phloroglucinol, reaching 50% at the highest concentration tested in TK6 cell line. 
In co-incubation with imatinib (at IC30) showed an antiproliferative effect in both cell lines, higher 
in TK6 cells with inhibition reaching 75% when compared with the control. 
The decrease in cell proliferation could be due to increased cell death and/or decrease 
of mitosis rate. In our study, the decrease of cell viability and cell proliferation of doxorubicin 
could be partially explained by increase of oxidative DNA damage and apoptotic levels. 
However, imatinib, fucoxanthin and phloroglucinol did not show ability to induce DNA damage 
and cell death through apoptosis. Previous studies already demonstrated that induction of 
apoptosis is one of the main mechanisms behind the anticancer activity of both natural 
compounds. However, a very important characteristic of both cell lines is their apoptosis 
reluctance, which can explain the low levels of cell death (detected by nuclear condensation 
assay) in this work. The antiproliferative effects of fucoxanthin and phloroglucinol could possibly 
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not be related with induction of DNA damage since no effects were observed by comet assay. 
However, the presented data are not enough to draw a definitive conclusion. 
 Even with the excellent advances in CML treatments, patients (mainly in blast crisis) 
remain without adequate therapies, so alternative treatments are necessary. As future 
perspectives, and having in consideration our results, since fucoxanthin and phloroglucinol 
appear to have some anticancer activity in the tested cell lines it will be interesting to 
understand how these natural compound act. First, is necessary to finish the analysis of the 
data from comet assay to determine the real levels of DNA damage. The next step is to use 
other assays to confirm the apoptosis induction (e.g. TUNEL, annexin V, cytochrome c release 
and caspases activation) using longer exposure times. Then other types of assays can be used 
to explore the exact mechanisms involved in the antiproliferative effects (e.g. assessment of 
mitochondrial membrane potential, cell cycle arrest, determination of reactive oxygen species 
(ROS) generation, selective gene expression and signaling pathways activation related with 
cell proliferation). It would be of interest to further investigate the action of these compounds in 
normal cell lines to determine the anticancer specificity and if possible include primary cells in 
the study. 
 The search for natural compounds with an anticancer activity that could work alone or 
co-incubated with existing anticancer drugs is one important field to investigate. A deep 
understanding of the molecular mechanisms involved are needed to develop targeted and 
selective therapies. Here, we reported for the first time the potential of fucoxanthin to enhance 
the efficacy of anticancer drugs such as doxorubicin (in K562 cells) and imatinib (K562 and 
TK6 cells) while phloroglucinol increase the effect of imatinib in both cell lines. Increase the 
therapeutic efficiency and minimize the toxicity against normal cells may bring huge benefits to 
patient so all the efforts to address these goals are welcome. 
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P1. Cell culture 
Principle 
The technique allows the cells to grow and be maintained outside the body, this 
provides us an opportunity to study the biochemistry and molecular biology associated with 
both normal and cancer cell lines. George Gey developed, in 1951, the first continuous human 
cancer cell line (HeLa).  The great advantage of cell lines is their ability to provide a renewable 
source of cell material that can be used in several types of studies. Yet sometimes the in vitro 
culture does not reflect most of the clinical cases. Cells can either grow adherent or in 
suspension, the majority are adherent to a “substrate” such as plastic or glass and the growth 
is in monolayer. Regarding the neoplastic cells, they are initially extracted from tumors and 
cultivate in appropriate medium with certain additives for growth. The maintenance of some 
physical environmental conditions is required for the optimal cell growth and to maintain durable 
cultures, such as the temperature at 36.5 °C ± 1° C, pH ideally around 7.4, CO2 atmosphere 
frequently at 5 % and control O2 tension (Langdon 2004, Cree 2011). 
In an initial phase, after defrosting, the cells should be only maintained, being subjected 
to successive passages/dilutions only when the confluence is reached (during at least two 
weeks), to ensure the stabilization of the growth. After that, the cells can be used to perform 
the desired experimental assays. All the cells pass through some well-defined stages of growth, 
the “lag phase” characterized for a relatively slower growth right after a passage. Then the 
culture will reach the most rapid phase of growth, called “log phase”. Finally, with the high cell 
density, space starts to be less and the medium poor, the growth rate decreases again and this 
is referred as “plateau phase” (Langdon 2004). 
The culture should be regularly checked (daily if possible) macroscopically and 
microscopically. Regarding the microscope observation, the morphology and cell density is 
evaluated, and the possible presence of fungus and bacteria in the culture. Macroscopically, 
the color and turbidity are the most important aspect to be considered. The color will indicate a 
change in the pH of the medium (in the present of phenol red). So, the medium should be 
renewed frequently to avoid the lack of specific nutrients or the acidification of the medium, the 
frequency of the medium renewal will depend on the cell lines and their growth rate. The 
increase of turbidity could indicate the presence of contamination (Langdon 2004, Freshney 
2006). 
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Materials 
• Humidified, controlled temperature/CO2 incubator 
• Inverted phase contrast microscope (e.g. OLYMPUS SKX41, Japan) 
• Laminar flow hood 
• Neubauer chamber 
• T25 cell culture flasks 
 
Assay solutions and reagents 
• Antibiotics (100U/ml penicillin and 100 µg/ml streptomycin) 
• Cell culture medium (e.g. RPMI) 
• Fetal Bovine Serum (FBS) 
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Work solutions preparation 
(1) Cell culture medium (RPMI) 
 Final concentration Weight / Volume 
RPMI 10.4 g/l 5.2 g 
Sodium bicarbonate 2 g/l 1 g 
Sodium pyruvate 110 mg/l 55 mg 
HEPES 10 mM 1.192 g 
FBS 10% 50 ml 
Penicillin / Streptomycin 1% 5 ml 
 
Weight and dissolve the reagents in ultrapure water to a final volume of 445 ml and mix 
until completely dissolved. Adjust pH to 7.4. Inside the laminar flow hood, filtrate the solution 
using a filter with 0.2 µm pore. Add FBS and antibiotics (penicillin/streptomycin), seal properly 
and store at 4 °C. Prepare one aliquot of 50 ml for each cell line to prevent the contamination 
of the stock solution of medium. All the mediums should be daily checked to avoid 
contamination. 
 
General guidelines 
Starting a new culture: 
1. To start a new culture of cells, thaw an aliquot of frozen cells by mixing them with the 
appropriate cell culture medium. This process must be fast in order to avoid cytotoxicity 
from the DMSO used in the freezing medium. 
2. Pipette the cells into a sterile centrifuge tube. 
3. Add more medium into the centrifuge tube (approx. 10 ml in total).  
4. Centrifuge the cells at 1300 rpm for 5 min. 
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5. Discard the medium with DMSO and add 5 ml of fresh and warm medium. Resuspend 
the pellet and transfer to a sterile cell culture flask. 
6. Incubate at 37 ºC and 5% CO2 in a humidified incubator. The flask should be always 
standing vertically (for non-adherent cells). 
 
Routine feeding and maintenance for non-adherent cells: 
1. Medium containing cells must be centrifuged in a sterile manner, at 1300 rpm for 5 min. 
2. Resuspended the pellet in fresh medium and transfer to a sterile cell culture flask. 
 
Subculture of non-adherent cells: 
1. Cell suspension should be checked to ensure that the cells are in late log/early plateau 
phase and to confirm that the cells are healthy and free of contamination. 
2. The cell suspension can then either be counted if an accurate cell density is required, 
or the suspension can simply be “split” into an appropriate ratio (1/5 – 1/10).  
3. Cell culture flasks are then returned to the CO2 incubator. After 24 h, the culture should 
be checked to ensure that the pH of the medium is approx. pH 7.4. 
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P2. Viability assay 
Principle 
There is a wide variety of assays designed to evaluate cellular drug sensitivity. These 
assays are mainly divided into two groups: The measurement only of cytotoxicity and those 
that measure the cell proliferation. Cytotoxicity assays at short-term allow assessing the direct 
cytotoxic effect of the treatment. The proliferation assays require exposure for long-term to 
assess effects on the cell ability to proliferate (Langdon 2004). The cytotoxic and proliferative 
effects can be assessed through cell viability assays such as trypan blue dye exclusion 
(Langdon 2004). However, other types of assays are available to assess cell viability. 
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Materials 
• 24-multiwell culture plate 
• Inverted phase contrast microscope (e.g. Olympus SKX41, Japan) 
• Microcentrifuge tube 
• Neubauer chamber 
 
Assay solutions and reagents 
• Cell culture medium (e.g. RPMI) 
• Trypan blue 
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General guidelines 
Cell preparation:  
1. In sterile conditions, plate 500 µl of cells in a 24-multiwell culture plate with the 
appropriate cellular density (K562: 0.3 x 106 cell/ml and TK6: 0.2 x 106 cell/ml) and 
incubate with the desired treatments.  
2. Cells should be incubated for 24 h in a humidified incubator at 37 °C and 5% CO2. 
3. When the incubation time is complete, the content of each well is transferred to a 
microcentrifuge tube and centrifuged for 5 min at 1800 rpm.  
4. Discard the supernatant and resuspend the pellet with 500 µl of fresh medium. Transfer 
100 µl of each condition to a new 24-multiwell culture plate and fill until 500 µl with fresh 
medium. Incubate more 48 h in a humidified incubator at 37 °C and 5% CO2. 
5. The remaining cellular suspension is used to count the cellular density after 24 h of 
treatment using 10 µl of trypan blue in the Neubauer chamber (1:1), where live cells 
with intact cell membranes remain unstained. For each condition were used the mean 
of four squares counted in the Neubauer chamber – Cytotoxicity assay. 
6. At the end of 48 h the cellular density was also determined by the same method – 
Proliferation assay.  
 
Calculations: 
• Cytotoxicity assay: The percentage of cellular viability for each condition was 
calculated based on the final control (t = 24 h), using the following equation: 
% viability = 
"#$/&$	()*+,-	.	/001-,/*,	123452,  
• Proliferation assay: The first step is to calculate the total suspension growth (TSG) 
using the density plated (t=0) and the cell density at the 72 h. Then is calculated the 
relative suspension growth that has in consideration the control. The respective 
equations are represented bellow: 
TSG = 1-,/*,	(789)1-,/(*,	)(0	9) 
RSG = ;<=	()*+,-;<=	123452,	
	79	
	
P3. Comet assay  
Principle 
The alkaline comet assay, also known as single cell gel electrophoresis, is a widely 
used method to measure in vitro and in vivo DNA damage (Neri et al. 2015). It detects strand 
breaks (SBs) and alkali-labile sites since a few hundred to several thousand breaks per cell. 
This technique allows to measure from low endogenous damage levels to a considerable 
amount of damage that can be caused experimentally without killing cells. The digestion of 
some nucleoids, after lysis, which present certain lesion-specific repair endonucleases enable 
the measurement of others damage than SBs, e.g. formamidopyrimidine DNA glycosylase 
(FPG) has been widely used to detect altered purines, which are converted to breaks by the 
enzyme (Azqueta and Dusinska 2015, Langie et al. 2015). The DNA damage or, in other words, 
the percentage of DNA in the tail, estimated by fluorescence staining using DAPI and 
observation under a fluorescence microscope reflects the amount of DNA breaks (Azqueta et 
al. 2011). 
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Materials 
• 6-multiwell culture plate 
• Centrifuge tubes 
• Coplin jar 
• Cover slides (20 x 20 mm) and cover slides (22 x 22 mm) 
• Electric power supply 
• Fluorescence microscope (e.g. Olympus IX71, Japan) 
• Horizontal electrophoresis tank Microwaves 
• Metal tray  
• Microcentrifuge tube 
• Microscope slides 
• Thermoblock 
 
Assay solutions and reagents 
• 0.5% (w/v) Low melting point (LMP) Agarose 
• 1% (w/v) Normal melting point (NMP) Agarose  
• Phosphate buffered saline (PBS) 
• Buffer F (pH 8) 
• DAPI staining solution (1 µg/ml) 
• Electrophoresis buffer (pH 13) 
• Lysis solution (pH 10) 
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Work solutions preparation 
(1) Phosphate Buffered Saline (PBS) – 1L 
 Final concentration Weight 
NaCl 137 mM 8 g 
KCl 2.7 mM 0.2 g 
Na2PO4 10 mM 1.44 g 
KH2PO4 2 mM 0.24 g 
 
Dissolve the reagents above in 800 ml of ultrapure water. Adjust pH to 7.4. Add necessary 
water for a final volume of 1 L. If necessary, autoclave the solution to sterilize and store at 4 
ºC. 
 
(2) 1 % NMP Agarose  
To prepare 200 ml of NMP agarose (necessary volume to prepare between 100 and 150 
slides) weight 2 g of agarose and add 200 ml of distillate water. Warm in microwaves to dissolve 
the powder, and keep the solution in a bath at 60 °C. 
 
(3) 0.5% Low Melting Agarose 
Weight 1 g of LMP agarose and add 200 ml of PBS (without calcium and magnesium). 
Warm in microwaves to dissolve, make aliquots of 3 ml and store at 4 ºC. 
 
 
 
 
	82	
	
(4) Lysis buffer, pH 10 – 1 L 
 Final concentration Weight 
NaCl 2.5 M 146.1 g 
Na2EDTA 100 mM 37.22 g 
Tris Base 10 mM 1.211 g 
 
Dissolve the reagents listed above in 800 ml of ultrapure water. Add approximately 7 g of 
NaOH to help dissolve. When all the reagents are totally dissolved, adjust the pH to 10 with 
NaOH. Add ultrapure water until a final volume of 1 L and store at 4 °C. 
Add immediately prior to use: TRITON X-100 1% (v/v) (e.g. 1 ml per 100 ml) 
 
(5) Buffer F (stock solution 10X) – 1L 
 Final concentration Weight 
HEPES 40 mM 95.32 g 
KCl 0.1 M 74.56 g 
EDTA 0.5 mM 1.86 g 
BSA 0.2 mg/ml 2.0 g 
 
Weight all the reagents and dissolve in approximately 600 ml of distillate water. Adjust 
the pH to 8.0 with KOH 10 M and fill with distillate water until 1 L. Prepare aliquots of 50 ml and 
keep them at -20 °C. 
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(6) Electrophoresis buffer - 1L 
 Final concentration Weight 
NaOH 0.3 M 12 g 
EDTA 1 mM 0.37 g 
 
Dissolve the powder in distillate water and adjust the pH to 13. Store at 4 °C, maximum 
1 week. 
 
General guidelines 
Slide preparation: 
Prepare the slides to submerge in 1% of NMP agarose at 60 °C, clean the back side 
and let it dry overnight horizontally. The next day it should be marked with a pencil the side with 
agarose. The slides with agarose can be stored during months at room temperature and 
protected from light and dust. 
 
Cells preparation: 
1. Plate the cells (K562: 0.3 x 106 cell/ml and TK6: 0.2 x 106 cell/ml) with the desired 
treatments in a 6-multiwell culture plate and incubate in a humidified incubator at 37 °C 
and 5% CO2 for 24 h. Note: In this case, the protocol is described for non-adherent 
cells. For adherent cells after plating is necessary a period for cell adhesion before add 
the treatments. 
2. After the incubation time, transfer the content of each well to a centrifuge tube previously 
identified. Wash each well with 1 ml of PBS to ensure the passage of all the cells and 
transfer again to the respective centrifuge tube. 
3. Centrifuge to remove the treatment at 1200 rpm for 5 min at 4 °C (from now on the cells 
should be kept on ice). 
4. Remove the supernatant and add 500 µl of ice-cold PBS in each centrifuge tube. 
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5. Centrifuge at 1500 rpm for 5 min at 4 °C. 
6. Remove the supernatant and resuspend the pellet, count the cells and calculate the cell 
density for each condition. 
7. Adjust cell density to 1 x 106 cell/ml using ice-cold PBS. 
 
Inclusion of the cells in agarose: 
1. Warm in microwaves the LMP agarose tubes (previously prepared) submerged in water 
(always avoiding the evaporations). 
2. Once in the liquid stage, transfer the tubes to a thermoblock to keep the temperature at 
37 °C. 
3. Prepare a metal tray on ice to dispose of the slides after preparing the gels. 
4. Identified all the slides, each condition have three slides: “lysis”, “FPG” and “buffer F”. 
5. In a microcentrifuge tube, add 90 µl of cellular suspension plus 420 µl of LMP agarose 
and resuspend with circular movements. 
6. Apply aa drop of 70 µl in each slide (2 gels/slide) and immediately cover each drop with 
a 20 x 20 mm cover slide. 
7. Transfer the slides to the metal tray and when the gels start to have an opaque color 
(around 10 min after), means that the gel is solidified, remove the cover slides by sliding 
to one side. 
 
Nucleoid obtaining: 
1. Submerge the slides in coplin jar with lysis solution (previously prepare with TRITON X-
100 and stored at 4 °C) during 1 h. Keep the slides for lysis separated from the ones 
for “FPG” and “buffer F”. 
 
Enzymatic treatment: 
1. Transfer the slides for “FPG” and “buffer F” to a coplin jar with buffer F at 4 °C for 5 min. 
Repeat the washes three times. 
2. Meanwhile, defrost the FPG and dilute them to the desired concentration using buffer 
F. Keep the enzyme always on ice. 
	85	
	
3. After the washes, put the slides in a metal tray on ice (certify that the tray is completely 
horizontal). Add 45 µl of FPG in the slides for “FPG” and 45 µl of buffer F in the slides 
for “buffer F” and cover them with a 22 x 22 mm cover slide. 
4. Transfer the metal tray to a container with warm water and incubate at 37 °C for 30 min. 
5. After the incubation time with the enzyme, put the tray again on ice to stop the enzymatic 
reactions. 
6. Remove the cover slides from the slides with FPG and buffer F sliding to one side. 
7. Put all the slides (from lysis, FPG, and buffer F) in the same way into the electrophoresis 
tank with electrophoresis buffer (1 L) at 4 °C (be sure that the tank is leveled) for the 
alkaline treatment. 
8. Incubate for 40 min at 4 °C to unwind the DNA. 
 
Electrophoresis: 
1. After the alkaline treatment, turn on the electrophoresis and run the gels for 20 min at 
25 V (1 V/cm). 
2. Wash the slides with ice-cold PBS using the coplin jar for 10 min at 4 °C. 
3. Wash again the slides, this time with ice-cold distillate water for 10 min at 4 °C. 
4. Dispose the slides on a horizontal surface at room temperature until the next day to dry. 
 
Microscope: 
1. With the lights turned off, add 30 µl of DAPI staining solution at 1 µg/ml to each gel and 
apply a 22 x 22 mm cover slide. Incubate for 20 min at room temperature. 
2. Turn on the computer and the fluorescence microscope (Olympus IX71, Japan). 
3. Put the slide in the microscope (20x) and turn on the fluorescence lamp. 
4. Count 50 comets in each gel, preferentially in the middle of the gel. The percentage of 
tail intensity was measured using OpenComet software (Gyori et al. 2014). 
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P4. Nuclear condensation 
Principle 
Apoptosis is a type of cell death that present specific morphological features, such as 
rounding-up of the cell, retraction of pseudopods, reduction nuclear volume, chromatin 
condensation, nuclear fragmentation, plasma membrane blebbing, amongst others (Kroemer 
et al. 2009). During apoptosis, the DNA that normally already contains some condensation, is 
strongly condensed and in the late stage occurs the formation of the “apoptotic bodies” (Toné 
et al. 2007). 
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 Materials 
• 24-multiwell culture plate 
• Centrifuge tubes 
• Cover slides (22 x 22 mm) 
• Cytocentrifuge filters 
• Cytospin Cytocentrifuge (Thermo Scientific, USA) Hydrophobic barrier pen 
• Fluorescence microscope (e.g. Olympus IX71, Japan) 
• Microcentrifuge tubes 
• Poly-L-lysine microscope slides 
 
 
	87	
	
Assay solutions and reagents 
• 4% Paraformaldehyde 
• 50% Glycerol solution 
• DAPI staining solution 
• Phosphate Buffered Saline (PBS) 
 
Work solution preparation 
(1) 4% Paraformaldehyde (PFA) 
 Final concentration Weight 
Paraformaldehyde (PFA) 4% 4 g 
 
Add 4 g of PFA in 100 ml of PBS. Place the solution in a 60 °C water bath. Be careful 
with the vapors, check the solution frequently. When completely dissolve, wait until the solution 
cold down and adjust the pH to 7.4. Store at -20 °C in aliquots of 50 ml. 
 
(2) DAPI staining solution (1 µg/ml) 
Dilute the stock solution of 100 µg/ml in distilled water. Store at -20 °C, protected from 
the light. 
 
(3) 50% Glycerol solution 
Add 5 ml of pure glycerol in 5 ml of PBS (1x). The glycerol is very viscous, vortex if 
needed. Store at 4 °C. 
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General Guidelines 
Cell preparation: 
1. Plate the cells (K562: 0.15 x 106 cell/ml and TK6: 0.1 x 106 cell/ml) and incubate with 
the desired treatments in a 24-multiwell culture plate for 48 h at 37 °C and 5% CO2 
(Note this protocol was done in non-adherent cells). 
2. Transfer the content of each well into a centrifuge tube labeled (resuspend in the well 
to ensure the passage of all the cells). 
3. Wash, each well, with 1 ml of PBS, and recover the PBS into the respective tube. 
4. Centrifuge the tubes at 1300 rpm for 10 min. 
5. Discard the supernatant until 500 µl and resuspend the remaining volume with 3 ml of 
PBS. 
6. Centrifuge the tubes at 1300 rpm for 10 min. 
7. Discard the supernatant until 500 µl and resuspend the remaining volume with 2 ml of 
4% PFA (previously defrosted in a bath at 37 °C) and incubate for 20 min at 37 °C. 
8. Add more 4 ml of PBS above the PFA. 
9. Centrifuge the tubes at 1300 rpm for 10 min. 
10. Discard the supernatant until 500 µl, resuspend and collect the remaining volume into 
labeled microcentrifuge tubes. 
11. Store at 4 °C. The samples can be stored for a few months. 
 
Nuclear condensation: 
1. Label poly-L-lysine microscope slides (two samples per slide), put them in the Cytospin 
Cytocentrifuge frames with the filters.  
2. Pipette 100 µl of cell sample into the respective cytocentrifuge tube. 
3. Run the Cytospin Cytocentrifuge at 500 rpm for 5 min. 
4. Disassemble the frames and flip each slide to put another sample. 
5. Pipette between 100 - 50 µl of cell sample into the respective Cytospin Cytocentrifuge 
tube. 
6. Run the Cytospin cytocentrifuge at 500 rpm for 5 min. 
7. Circle the samples with a hydrophobic barrier pen and leave them to air dry. 
8. Wash the slides three times with PBS, for 5 min each turn. 
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9. Incubate 20 µl of DAPI staining solution for 10 min in the dark. 
10. Add a drop (6 µl) of 50% glycerol to each sample and cover with a 22 x 22 mm coverslip. 
11. Store the slides at -20 °C, protected from the light until the analysis. 
 
Analysis of nuclear condensation: 
Observe the slides under a fluorescence microscope. Count at least 300 cells, (at least 
three microscopic fields) for each sample. Register the total number of cells and the number of 
cells that present apoptotic signals (condensed nuclei). The percentage of cells with condensed 
nuclei is determined according to the ratio between the number of cells showing condensed 
nuclei and the total number of cells.  
 
